WO1998023269A1 - Polythiophene anti-tumor agents - Google Patents
Polythiophene anti-tumor agents Download PDFInfo
- Publication number
- WO1998023269A1 WO1998023269A1 PCT/US1996/019118 US9619118W WO9823269A1 WO 1998023269 A1 WO1998023269 A1 WO 1998023269A1 US 9619118 W US9619118 W US 9619118W WO 9823269 A1 WO9823269 A1 WO 9823269A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- thienyl
- alkyl
- substituted
- mono
- group
- Prior art date
Links
- 0 *c1ccc(-c2ccc(-c3c[s]cc3)[s]2)[s]1 Chemical compound *c1ccc(-c2ccc(-c3c[s]cc3)[s]2)[s]1 0.000 description 2
- PMPDDPJYARBNGV-UHFFFAOYSA-N O=Cc1ccc(-c2ccc(-c3ccc[s]3)[s]2)[s]1 Chemical compound O=Cc1ccc(-c2ccc(-c3ccc[s]3)[s]2)[s]1 PMPDDPJYARBNGV-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/18—Radicals substituted by singly bound hetero atoms other than halogen by sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/22—Radicals substituted by doubly bound hetero atoms, or by two hetero atoms other than halogen singly bound to the same carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/28—Halogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/32—Oxygen atoms
Definitions
- the present invention relates to compositions and a method for treating a patient having a tumor. More specifically, the present invention relates to the treatment of such patients with an effective amount of a polythiophene derivative.
- the control and cure of cancer represents one of our most challenging health problems.
- the treatment of cancer can be approached by several modes of therapy including surgery, radiation, chemotherapy or a combination of any of these treatments.
- Chemotherapy continues to be an indispensable therapy for inoperable or metastatic forms of the disease.
- the selection of natural compounds, or the synthesis of new compounds having effective anticancer activity is complicated by the still limited knowledge of cancer cell biology and biochemistry. Therefore, development of new effective anti-tumor agents will remain heavily dependent on screening compounds to discover novel compounds having cytotoxic activity.
- such compounds exhibit enhanced cytotoxicity against tumor cells relative to their cytotoxicity to normal cells.
- Natural products have a history of providing novel, clinically useful anticancer drugs. Many active natural products have also served as prototypes for the development of new analogs of clinical and preclinical importance. Some specific examples are the Vinca alkaloids (vincristine, vinblastine, vindesine and vinorelbine) , podophyllotoxins etoposide and teniposide) , taxanes (taxol, taxotere) , camptothecins (10-hydroxycamptothecin, 9- dimethylaminomethylcamptothecin, 9-aminocamptothecin and CPT-11) , ho oharringtonine, adriamycin, daunomycin, bleomycin, mitomycin, idamycin, plicamycin and dactino ycin.
- Vinca alkaloids vincristine, vinblastine, vindesine and vinorelbine
- podophyllotoxins etoposide and teniposide taxanes
- NCI National Cancer Institute
- This in vitro prescreening system is based on the measurement of antitumor cytotoxicity against human tumor cell line panels consisting of approximately 60 cell lines of major human tumors (including leukemia and slower growing tumor cells such as lung, colon, breast, skin, kidney, etc.).
- the most important advantage of the new in vitro screening panels is the opportunity to identify compounds that are selectively more cytotoxic to cells of slowly growing solid tumors than to rapidly growing leukemia cells.
- Thiophenes are sulfur containing heterocyclic compounds that are distributed widely among the species of the Asteraceae (Compositaie) family, including many species with known medicinal uses.
- the natural thiophene compounds are thought to play an important role in the chemical defense of plants against herbivorous insects and other pests.
- Natural thiophenes have been previously described as having cytotoxic activities upon exposure to long wavelength ultraviolet light. Photochemical studies suggest that thiophene phototoxicity is based primarily on the production of toxic singlet oxygen by a type II photodynamic process. However, polythiophene compounds also exhibit cytotoxic activity in the absence of light activation. More particularly, we have demonstrated that the polythiophene derivatives of the present invention are effective antitumor agents.
- n 0, 1 or 2
- R ⁇ is H, CHO, CH 2 0H or CH 2 NH 2
- R 2 and R 3 are independently optionally substituted 2- or 3- thienyl.
- the present invention is directed to polythiophene compounds, their pharmaceutical compositions and methods utilizing such compounds/compositions for treating patients having tumors.
- the polythiophene compounds are effective antitumor agents against slow growing tumors. Generally they have been found to exhibit high selective cytotoxicity for individual tumor cell lines.
- the compounds of the present invention are polythiophene compounds of the formula:
- n 0, 1 or 2 ,
- R j _ is H, CH 2 0H, CHO, CH 2 NH 2 ,
- R 4 is H, CO(CH 2 ) 2 C0 2 H, (CH 2 ) 2 OCH 3 , C 1 -C 4 alkyl, C0C 1 -C 17 alkyl, or tetrahydropyranyl ;
- R 5 is H or ⁇ C alkyl
- R 6 and R 7 are independently H, C ⁇ ⁇ -C ⁇ j alkyl, or mono- or di- hydroxyC 2 -C 4 alkyl;
- R 8 is C- L -Cy alkyl, or C ⁇ C ? alkenyl
- R 9 and R 10 are independently H, C- ⁇ C j alkyl, COOR 5 , CN, CH(OR 4 )COOR 5 , Br, CO-thienyl, COC 6 H 4 OH(p);
- R l ⁇ is NHR 4 or 0R 5 ;
- R 12 is COOR 5 , CH(OR 4 )CH 2 OR 13 or CH(OCOC 1 -C 4 alkyl) CH 2 OR 5 ;
- R 13 is H, COCH 2 CH 2 COOH, or C0C 1 -C 17 alkyl; cyclodextrin complexes of such compound and when R 2 or R 3 is thienyl substituted with CH 2 NR 6 R 7 , the pharmaceutically acceptable salt of the compound represented thereby; with the proviso, that when R-L is H, R 2 is selected from the group consisting of 3-thienyl, di- substituted 2-thienyl, hydroxymethyl- or aminomethyl- substituted 2-thienyl, 3- formy1-2-thienyl and mono- or di- substituted 3-thienyl, and R 3 is selected from the group consisting of 3-thienyl, di- substituted 2-thienyl, hydroxymethyl- or aminomethyl- substituted 2-thienyl, mono- or di- substituted 3-thienyl and formyl substituted 2-thienyl.
- CH 2 NH 2 , CH 2 0H or CHO exhibit cytotoxic selectivity against transformed human cells.
- Still another preferred group of polythiophene compounds of this invention are those of the above formula wherein R 2 is optionally substituted 2-thienyl and R 3 is 3- or 4-substituted-2-thienyl wherein the substitutes are selected from CH 2 OH, CHO and CH 2 NH 2 .
- n 0, 1 or 2
- R ⁇ is H, CH 2 OH, CHO, CH 2 NH 2 ,
- R 2 is selected from the group consisting of 2-thienyl, 3-thienyl, mono- or di- substituted 2-thienyl, or mono- or di- substituted 3-thienyl
- R 3 is selected from the group consisting of 3-thienyl, mono- or di- substituted 3- thienyl and di- substituted 2-thienyl
- R 4 is H, CO(CH 2 ) 2 C0 2 H, (CH 2 ) 2 OCH 3 , C 1 -C 4 alkyl, or 00 ⁇ - C 17 alkyl ;
- R 5 is H or C ⁇ C- ? alkyl;
- R 6 and R 7 are independently H, C- ⁇ alkyl, or mono- or di- hydroxyC 2 -C 4 alkyl;
- R 8 is C-L-C-7 alkyl, or C_-C- j alkenyl
- R 9 and R 10 are independently H, C_-C ⁇ alkyl, COOR 5 , CN, CH(OR 4 )COOR 5 , Br, CO-thienyl, COC 6 H 4 OH(p); R l ⁇ is NHR 4 or OR 5 ;
- R 12 is C00R 5 , CH(OR 4 )CH 2 OR 13 or CH (OCOC-L- ⁇ alkyl) CH 2 OR 5 ;
- R 13 is H, COCH 2 CH 2 COOH, or COC-L-C- ⁇ alkyl; cyclodextrin complexes of such compound and when R 2 or R 3 is thienyl substituted with CH 2 NR 6 R 7 , the pharmaceutically acceptable salt of the compound represented thereby.
- the polythiophene compounds of this invention are readily formulated into pharmaceutical compositions, also within the scope of this invention, for use in the presently described method for treatment of patients having tumors.
- the pharmaceutical composition comprises an anti-tumor effec- tive amount of a polythiophene compound of the formula:
- n 0, 1 or 2 ,
- R 4 is H, CO(CH 2 ) 2 C0 2 H, (CH 2 ) 2 OCH 3 , or COC 1 -C 17 alkyl;
- R 5 is H or C ⁇ -C ⁇ alkyl;
- R 6 and R 7 are independently H, C 1 -C 4 alkyl, or mono- or di- hydroxyC 2 -C 4 alkyl;
- R 8 is C 1 -C 7 alkyl, or ⁇ -C y alkenyl
- R 9 and R 10 are independently H, C 1 -C 7 alkyl, COOR 5 , CN, CH(OR 4 )COOR 5 , Br, CO-thienyl, or COC 6 H 4 OH(p) ;
- R ⁇ is NHR 4 or OR 5 ;
- R 12 is C00R 5 , CH(OR 4 )CH 2 OR 13 or CH(0C0C 1 -C 4 alkyl) CH 2 OR 5 ;
- R 13 is H, COCH 2 CH 2 COOH, or C0C 1 -C 17 alkyl; cyclodextrin complexes of such compound and when R 2 or R 3 is thienyl substituted with CH 2 NR 6 R 7 , the pharmaceutically acceptable salt of the compound represented thereby; with the proviso, that when R x is H, R 2 is selected from the group consisting of 2-thienyl, 3-thienyl, mono- or di- substituted 2-thienyl, or mono- or di- substituted 3- thienyl, and R 3 is selected from the group consisting of 3- thienyl, mono- or di- substituted 2-thienyl, or mono- or di- substituted 3-thienyl, and a pharmaceutically acceptable carrier.
- n 0, l or 2 ,
- R ⁇ is H, CH 2 0H, CHO, CH 2 NH 2 ,
- R 2 is selected from the group consisting of 2-thienyl, 3-thienyl, mono- or di- substituted 2-thienyl, or mono- or di- substituted 3-thienyl
- R 4 is H, CO(CH 2 ) 2 C0 2 H, (CH 2 ) 2 OCH 3 , C 1 -C 4 alkyl or 00 ⁇ - C_ ⁇ alkyl;
- R 5 is H or C ⁇ C ⁇ alkyl
- R 6 and R 7 are independently H, C- ⁇ -C ⁇ alkyl, or mono- or di- hydroxyC 2 -C 4 alkyl;
- R 8 is C;L-C 7 alkyl, or C -C ⁇ alkenyl
- R 9 and R 10 are independently H, C_-C ⁇ alkyl, COOR 5 , CN, CH(OR 4 )COOR 5 , Br, CO-thienyl, or COC 6 H 4 OH(p) ;
- R l ⁇ is NHR 4 or OR 5 ;
- R 12 is COOR 5 , CH(OR 4 )CH 2 OR 13 or alkyl) CH 2 OR 5 ;
- R 13 is H, COCH 2 CH 2 COOH, or COC ⁇ C- ⁇ alkyl; cyclodextrin complexes of such compound and when R 2 or R 3 is thienyl substituted with CH 2 NR 6 R 7 , the pharmaceutically acceptable salt of the compound represented thereby, and a pharmaceutically acceptable carrier.
- the present compounds are readily prepared using art- recognized chemical-synthesis procedures as exemplified hereinbelow. The art is replete with descriptions of the chemistry and synthesis of thiophene and polythiophene compounds. Tables 1, 2, 3 and 4 hereinbelow show several polythiophene compounds that have been tested at the National Cancer Institute. The growth inhibition profiles of several polythiophenes are shown in Tables 5, 6 and 7. The unusually strong activities against solid tumors are predictive of significant therapeutic potency for the treatment of cancer.
- THP tetrahydropyranyl Ac: actyl TS: tosyl Et: ethyl TH: thienyl
- Table 5 The growth inhibition of the human cancer cell lines by polythiophene Log 10 GI 50 (M)
- Table 6 The growth inhibition of the human cancer cell lines by chemically modified a-polythiophene derivatives
- the cytotoxic activity of the present polythiophene compounds have been measured utilizing three different assays or screens.
- the first screen measures the cytotoxicity against a panel of sixty different human tumor cell lines.
- This assay provides data regarding the general cytotoxicity of an individual compound.
- this type of assay is useful in identifying compounds which have enhanced cytotoxic activity against slow growing tumors as compared to faster growing tumor cells such as leukemia tumor cell lines.
- the identification of such compounds is critical since previously identified antitumor agents have low cytotoxic activity against slower growing tumors.
- the specificity of a compound for a limited number of tumor cell lines also indicates that such a compound will likely be less cytotoxic to normal cells.
- the specificity of a cytotoxic compound for tumor cell lines relative to normal cells is an important characteristic of an effective antitumor agent. Antitumor cytotoxicity data for the National Cancer
- Relative cytotoxicity is displayed by projecting bars to the right or left of the mean, depending on whether cell sensitivity to a test compound is more or less than average. The length of a bar is indicative of differential cytotoxicity against a specific type of tumor cells or tumor panels.
- the cytotoxic selectivity is assessed by comparing compound cytotoxicity against transformed cells and normal cells. IC 50 values were compared between treated TBE cells (ras-transformed human bronchial epithelial cells) and NHBE cells (Normal human bronchial epithelial cells) .
- NMBE normal human bronchial epithelial cells
- TBE ras-transformed human bronchial epithelial cells
- the antitumor cytotoxicity of the thiophene compounds tested in the first two in vitro assays was measured by a microculture assay using either 3- (4 , 5-dimethylthiazol-2-yl) -2 , 5-diphenyltetrazolium bromide (MTT) or sulforhodamine B (SRB) .
- MTT 5-dimethylthiazol-2-yl
- SRB sulforhodamine B
- Table 8 Selective cytotoxicity against ras-oncogene transformed human bronchial epithelial cells
- This assay has an advantage over in vivo assay in that results are obtained within a week as opposed to several months.
- the assay was carried out in 96-well microtiter plates.
- the MTT assay is based on the production of a dark blue formazan product by dehydrogenase in the mitochondria of live tumor cells after exposure to drug for 6 days [M.C. Alley, D.A. Scudiero, A. Monks, M.L. Hursey, M.J. Czerwinski, D.L. Fine, B.J. Abbott, J.G. Mayo, R.H. Shoemaker and M.R.
- GI 50 Antitumor cytotoxicity is reported as GI 50 , effect drug dose at which cell growth is retarded to 50% of control culture of tumor cells.
- the active compounds are defined as those compounds having GI 50 values that are less than 10 -4 M or 10 ⁇ g/ml.
- the in vivo data was derived from experiments in which human tumors are transplanted into immune deficient mice and allowed to grow for two days prior to treatment with a polythiophene composition of this invention. See Example 48 and accompanying Tables 9 and 10. Data obtained from studies using heterotransplanted tumors in immune deficient mice are recognized as well-correlated with the effectiveness of these agents in clinical studies (Giovanella, B.C. et al. Cancer 52(7): 1146 (1983).
- the present invention further provides pharmaceutical formulations comprising an effective amount of a polythiophene compound for treating a patient having a tumor.
- an effective amount of the polythiophene compound is defined as the amount of the compound which, upon administration to a patient, inhibits growth of tumor cells, kills malignant cells, reduces the volume or size of the tumors or eliminates the tumor entirely in the treated patient.
- the effective amount to be administered to a patient is typically based on body surface area, patient weight, and patient condition. The interrelationship of dosages for animals and humans (based on milligrams per meter squared of body surface) is described by Freireich, E.J., et al., Cancer Chemother. Rep. , 50 (4): 219 (1966).
- Body surface area may be approximately determined from patient height and weight (see e.g., Scientific Tables, Geigy Pharmaceuticals, Ardley, New York, pages 537-538 (1970)).
- An effective amount of the polythiophene compounds in the present invention can range from about 5 mg/kg. to about
- 500 mg/kg more preferably from about 5 mg/kg to about 250 mg/kg, and most preferably about 5 to about 150 mg/kg.
- Effective doses will also vary, as recognized by those skilled in the art, dependant on route of administration, excipient usage and the possibility of co-usage with other therapeutic treatments including other anti-tumor agents, and radiation therapy.
- the pharmaceutical formulation may be administered via the parenteral route, including subcutaneously, intraperitoneally, intramuscularly and intravenously.
- parenteral dosage forms include aqueous solutions of the active agent, in a isotonic saline, 5% glucose or other well-known pharmaceutically acceptable liquid carrier.
- the polythiophene compound is dissolved in a saline solution containing 5% of dimethyl sulfoxide and 10% Cremphor EL (Sigma Chemical Company) .
- solubilizing agents such as cyclodextrins, which form specific, more soluble complexes with the present polythiophene compounds, or other solubilizing agents well- known to those familiar with the art, can be utilized as pharmaceutical excipients for delivery of the polythiophene compounds.
- the present compound can also be formulated into dosage forms for other routes of administration utilizing well- known methods.
- the pharmaceutical compositions can be formulated, for example, in dosage forms for oral administration in a capsule, a gel seal or a tablet.
- Capsules may comprise any well-known pharmaceutically acceptable material such as gelatin or cellulose derivatives.
- Tablets may be formulated in accordance with conventional procedure by compressing mixtures of the active polythiopene and solid carriers, and lubricants well-known to those familiar with the art. Examples of solid carriers include starch, sugar, bentonite.
- the compounds of the present invention can also be administered in a form of a hard shell tablet or capsule containing, for example, lactose or mannitol as a binder and a conventional fillers and tableting agents.
- the following examples are provided to illustrate various embodiments of Applicants' invention, and are not intended to in any way limit the scope of the invention as set forth in this specification and appended claims.
- the extract was dried, concentrated and separated by silica gel chromatography eluted first with ethyl acetate/n-hexane (1:9) to recover starting material, and then with ethyl acetate/n-hexane (3:7) to obtained 5-formyl- ⁇ -terthiophene.
- P0C1 3 (2 ml) was added into dimethyl formamide (30 ml) slowly under nitrogen gas atmosphere in ice bath and stirred for 1 hour.
- Ethyl propiolate (78 mg) was dissolved in benzene (3 ml) . 5-Iodo- ⁇ -terthiophene (0.2 g) was added immediately and stirred. A mixture of Cul (0.05 g) , benzyltriethylammonium chloride (0.05 g) , catalyst Pd(PPh 3 ) 4 (0.1 g) and 5 ml of NaOH solution (2.5 N) were mixed together. The temperature of the mixture was then raised to 40°C and stirred for 5 more hours. Then 5 ml of NH 4 C1 solution was added. The reaction solution was extracted with ethyl acetate.
- the extract was washed with 10 ml of HCl (10%) for 3 times, 50 ml of water twice and dried over anhydrous magnesium sulfate.
- the residual solid after evaporation was purified by silica gel column chromatography, eluted with ethyl acetate/n-hexane (1/3). Light yellowish product (0.21 g, 75%) was obtained and the melting point thereof was 67°C.
- Acetylene gas was bubbled into tetrahydrofuran (30 ml) for 30 minutes.
- Ethyl magnesium bromide 25 ml was added.
- the eluant was ethyl acetate/n-hexane (7/3) .
- the white platelet crystal thus obtained was further recrystallized with ethyl acetate/n-hexane mixture.
- the melting point of the product was 60°C.
- Phosphorus oxychloride (“P0C1 3 ”) (1 ml) was added into dimethyl formamide (20 ml) slowly under nitrogen gas atmosphere in ice bath and stirred for 1 hour.
- the dimethyl formamide solution (5 ml) of 5-hydroxymethyl- 2 , 2 '-bithiophene (0.5 g) was dropped in slowly.
- the mixture was stirred for half an hour at room temperature, then the temperature was raised to 50°C and was further stirred for 3 hours.
- the reaction solution was poured into potassium carbonate ice water solution. Then the solution was extracted with 100 ml of ethyl acetate. The extract was washed with water and dried over anhydrous magnesium sulfate.
- NSC code # 647453 5-Hydroxymethyl-5'-formyl-2, 2 '-bithiophene (0.2 g) and pyridine (1 ml) were mixed together. Acetic anhydride (1 ml) was added slowly into the mixture with stirring. Ethyl acetate (200 ml) and water (50 ml) were added 2 hours later. The ethyl acetate layer was washed with weak base, weak acid and water. The product was concentrated and purified by column chromatography, eluted with ethyl acetate/n-hexane (1/9) . Light yellowish crystals were obtained. The melting point of the crystal was 89-91°C.
- the yield was 95%.
- the residual solid was purified by column chromatography, eluted with ethyl acetate/n-hexane (3/7) . After removal of solvent, the residue was dissolved in 50 ml of tetrahydrofuran under nitrogen stream and dropped in 1 ml of Ethyl Grignard reagent and stirred at room temperature for 3 hours. The solution was monitored by thin layer chromatography. After the reaction was completed, then the solution was extracted with 300 ml of ethyl acetate and 50 ml of water. After removal of solvent, the residual solid was purified by column chromatography, eluted with ethyl acetate/n-hexane (3/7) .
- polythiophene compounds prepared in accordance with this invention are those represented by the following structural formulas.
- NSC 666165-Z/0-1/30
- Tumor cells were obtained from normal human bronchial epithelial cells transfected ' with plasmic HI carrying v-Harvey-ras (H-ras) oncogene via protoplast fusion (G.H. Yoakum, J.F. Lechner, E.W. Gabrielson, B.E. Korba, L. Malan-Shibley, J.C. Willey, M.G. Valerio, A.M. Shamsuddin, B.F. Trump and C.C. Harris, Science 227, 1174, 1985.
- the TBE cells were implanted subcutaneously on day 0 of the experiment. Each test group consists of five mice. The compounds tested were dissolved in a saline solution or a saline solution containing 5% of dimethylsulfoxide and 10% cremphor EL (Sigma Chemical Company, St. Louis, MO) , and were administered intraperitoneously starting on day 2. The solution was administered every four days for a total of four treatments. Tumor volumes were measured every week. The antitumor activity was measured as % of growth inhibition, which is defined by the percentage of the median tumor volume reduction per week of the treated mice divided by the median tumor volume per week of the controlled mice (Tables 9 and 10) .
- Tumor cells ras-transformed human bronchial epithelial cells (2.5 x 10 6 cells/mouse)
- Tumor cells ras-transformed human bronchial epithelial cells (4.0 x 10 6 cells/mouse)
- Tumor growth inhibition was determined by comparing the volume/weight of the tumors of the treated mice in the test group with that of the tumors in the control group mice. The data are presented as the percent of treated tumor volume/weight to control tumor volume/weight (T/C %) with the day the measurement was taken indicated in parenthesis.
- a. 660641 hydroxypropyl-B-cyclodextrin inclusion complex of 2-aminohydroxy- ⁇ - terthiophene tartarated (2:1 molar ratio; FW:3428) (Estimated 50% lethal dosage: 1550 mg/kg.)
- 647455 2-formyl-5"-hydroxymethyl- ⁇ -terthiophene
- 637388 2-hydroxymethyl - ⁇ -terthiophene
- 658878 2,4"- ⁇ lihydroxymethyl- ⁇ -terthiophene
- T/C tumor volume or weight of treated mice/tumor volume or weight of control (untreated) mice. The number shown in the parenthesis is the day when the tumor volume or weight is measured.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Novel polythiophene compounds useful as anti-tumor agents are described. Preferred compounds of formula (I) wherein n is 0-2 and R2 and R3 are optionally substituted 2-thienyl or 3-thienyl have been found to exhibit selective cytotoxic activity against transformed human cells. Pharmaceutical compositions containing the described polythiophene compounds are expected to exhibit good chemotherapeutic activity against slow growing tumors based on tumor cell line assays. A method for treating patients having tumors utilizing the disclosed polythiophene compounds is also described.
Description
POLYTHIOPHENE ANTI-TUMOR AGENTS Field of the Invention
The present invention relates to compositions and a method for treating a patient having a tumor. More specifically, the present invention relates to the treatment of such patients with an effective amount of a polythiophene derivative.
Government Rights
This invention was made with United States Government support under Grant No. 5 UOl CA50743-02, awarded by the National Cancer Institute. The United States Government has certain rights in the invention. This invention was made with the support of the Republic of China under National Science Council Project numbers 16006, 45202, 45208 and 30602 and Ministry of Economic Affairs Project Numbers 31X5110, 33A5100, 34B3300, 35M3100, 37A2100 and 13B12200. The Republic of China has certain rights in the invention.
Background and Summary of the Invention
The control and cure of cancer represents one of our most challenging health problems. The treatment of cancer can be approached by several modes of therapy including surgery, radiation, chemotherapy or a combination of any of these treatments. Chemotherapy continues to be an indispensable therapy for inoperable or metastatic forms of the disease. The selection of natural compounds, or the synthesis of new compounds having effective anticancer activity is complicated by the still limited knowledge of cancer cell biology and biochemistry. Therefore, development of new effective anti-tumor agents will remain heavily dependent on screening compounds to discover novel compounds having
cytotoxic activity. Preferably, such compounds exhibit enhanced cytotoxicity against tumor cells relative to their cytotoxicity to normal cells.
Natural products have a history of providing novel, clinically useful anticancer drugs. Many active natural products have also served as prototypes for the development of new analogs of clinical and preclinical importance. Some specific examples are the Vinca alkaloids (vincristine, vinblastine, vindesine and vinorelbine) , podophyllotoxins etoposide and teniposide) , taxanes (taxol, taxotere) , camptothecins (10-hydroxycamptothecin, 9- dimethylaminomethylcamptothecin, 9-aminocamptothecin and CPT-11) , ho oharringtonine, adriamycin, daunomycin, bleomycin, mitomycin, idamycin, plicamycin and dactino ycin. It is clear that natural products will continue to be important sources of novel anticancer agents. However, key to the success of novel antitumor drug development programs is the initial identification of potential antitumor agents. The mouse L1210 leukemia cell line was initially the preferred model system used for screening natural compounds for antitumor activity. However, the P388 murine leukemia system was found to be more sensitive and predictive than L1210 leukemia system, and has been used as primary screen during the past decade. Systematic screening for compounds exhibiting toxicity to these two leukemia cell lines has resulted in the isolation of a large number of active natural products. However, the anticancer activities of these compounds were predominantly in leukemia, lymphoma and a few rare tumors. Low clinical efficacy, or the lack of clinical efficacy of known chemotherapeutics against slower growing solid tumors, is a serious concern.
It has been recognized that the use of a single antileukemia screening system could bias the end results and lead to the isolation of compounds only active in the
treatment of fast growing tumors. In addition, the use of a single antileukemia screening system may not detect novel compounds with high specificities for particular cell lines. It is also likely that many novel compounds with possible anti tumor activity have remained undetected by the less sensitive in vivo models due to the low concentrations at which many active natural products occur.
Considering the diversity of tumors in terms of cell type, morphology, growth rate and other cellular characteristics, the U.S. National Cancer Institute (NCI) has developed a "disease-oriented" approach to antitumor activity screening (M.R. Boyd, in "Principle of Practice of Oncology" J.T. Devita, S. Hellman, S.A. Rosenberg (Eds.) Vol. 3, PPO Update, No. 10, 1989). This in vitro prescreening system is based on the measurement of antitumor cytotoxicity against human tumor cell line panels consisting of approximately 60 cell lines of major human tumors (including leukemia and slower growing tumor cells such as lung, colon, breast, skin, kidney, etc.). The most important advantage of the new in vitro screening panels is the opportunity to identify compounds that are selectively more cytotoxic to cells of slowly growing solid tumors than to rapidly growing leukemia cells.
Thiophenes are sulfur containing heterocyclic compounds that are distributed widely among the species of the Asteraceae (Compositaie) family, including many species with known medicinal uses. The natural thiophene compounds are thought to play an important role in the chemical defense of plants against herbivorous insects and other pests. Natural thiophenes have been previously described as having cytotoxic activities upon exposure to long wavelength ultraviolet light. Photochemical studies suggest that thiophene phototoxicity is based primarily on the production of toxic singlet oxygen by a type II photodynamic process. However, polythiophene compounds
also exhibit cytotoxic activity in the absence of light activation. More particularly, we have demonstrated that the polythiophene derivatives of the present invention are effective antitumor agents.
In accordance with this invention there is provided a method for the treatment of cancer which utilizes polythiophene compounds of the general formula:
Ri
R2 R3
wherein n is 0, 1 or 2 , Rλ is H, CHO, CH20H or CH2NH2, and R2 and R3 are independently optionally substituted 2- or 3- thienyl. Further in accordance with this invention there are provided novel cytotoxic compounds of the above formula and chemotherapeutic pharmaceutical compositions containing said compounds in anti-tumor effective amounts.
Additional objects, features, and advantages of the invention will become apparent to those skilled in the art upon consideration of the following detailed description of preferred embodiments exemplifying the best mode of the invention as presently perceived.
Detailed Description of the Invention
The present invention is directed to polythiophene compounds, their pharmaceutical compositions and methods utilizing such compounds/compositions for treating patients having tumors. The polythiophene compounds are effective antitumor agents against slow growing tumors. Generally they have been found to exhibit high selective cytotoxicity for individual tumor cell lines.
The compounds of the present invention are polythiophene compounds of the formula:
wherein n is 0, 1 or 2 ,
Rj_ is H, CH20H, CHO, CH2NH2 ,
R2 and R3 are independently selected from the group consisting of 2-thienyl, 3-thienyl, mono- or di- substituted 2-thienyl, or mono- or di- substituted 3- thienyl, wherein the thienyl substituents are selected from the group consisting of cyano, chloro, bromo, iodo, C1-C7 alkyl or haloalkyl, C^C-; alkenyl or haloalkenyl, C-^-^ alkanoyloxy methyl, CH2OR4, COR5, CH2NR6R7, CH(0R4)R8, CH=CR9R10, CH=NR11# CH2SC(NH)NH2 and G≡CR12 wherein
R4 is H, CO(CH2)2C02H, (CH2)2OCH3, C1-C4 alkyl, C0C1-C17 alkyl, or tetrahydropyranyl ;
R5 is H or ^C alkyl;
R6 and R7 are independently H, C^^-C^j alkyl, or mono- or di- hydroxyC2-C4 alkyl;
R8 is C-L-Cy alkyl, or C^C? alkenyl;
R9 and R10 are independently H, C-^Cj alkyl, COOR5, CN, CH(OR4)COOR5, Br, CO-thienyl, COC6H4OH(p);
Rlλ is NHR4 or 0R5;
R12 is COOR5, CH(OR4)CH2OR13 or CH(OCOC1-C4 alkyl) CH2OR5;
R13 is H, COCH2CH2COOH, or C0C1-C17 alkyl; cyclodextrin complexes of such compound and when R2 or R3 is thienyl substituted with CH2NR6R7, the pharmaceutically acceptable salt of the compound
represented thereby; with the proviso, that when R-L is H, R2 is selected from the group consisting of 3-thienyl, di- substituted 2-thienyl, hydroxymethyl- or aminomethyl- substituted 2-thienyl, 3- formy1-2-thienyl and mono- or di- substituted 3-thienyl, and R3 is selected from the group consisting of 3-thienyl, di- substituted 2-thienyl, hydroxymethyl- or aminomethyl- substituted 2-thienyl, mono- or di- substituted 3-thienyl and formyl substituted 2-thienyl. In one preferred embodiment of this invention there is provided anti-tumor polythiophenes of the above formula wherein n is 1, Rλ is H, R2 is 3-thienyl or substituted 3- thienyl and R3 is 2-thienyl or substituted 2-thienyl. Such polythiophene compounds, especially those wherein R2 is 3- thienyl and R3 is 2-thienyl optionally substituted with
CH2NH2, CH20H or CHO, exhibit cytotoxic selectivity against transformed human cells.
Other preferred compounds in accordance with this invention are those polythiophenes of the above formula wherein n is 1, ^ is hydrogen, R2 is hydroxymethyl 2- thienyl and R3 is 2-thienyl optionally substituted with
CH2NH2, CH2OH or CHO.
Still another preferred group of polythiophene compounds of this invention are those of the above formula wherein R2 is optionally substituted 2-thienyl and R3 is 3- or 4-substituted-2-thienyl wherein the substitutes are selected from CH2OH, CHO and CH2NH2.
Another group of polythiophene compounds within the scope of this invention are compounds of the formula:
Rχ is H, CH2OH, CHO, CH2NH2 ,
R2 is selected from the group consisting of 2-thienyl, 3-thienyl, mono- or di- substituted 2-thienyl, or mono- or di- substituted 3-thienyl, and R3 is selected from the group consisting of 3-thienyl, mono- or di- substituted 3- thienyl and di- substituted 2-thienyl, wherein the thienyl substituents are selected from the group consisting of cyano, chloro, bromo, iodo, C_-C-j alkyl or haloalkyl, -^-C-j alkenyl or haloalkenyl, C1-C4 alkanoyloxy methyl, CH2OR4, COR5, CH2NR6R7, CH(OR4)R8, CH=CRgR10, CH=NR11, CH2SC(NH)NH2 and C≡CR12 wherein
R4 is H, CO(CH2)2C02H, (CH2)2OCH3, C1-C4 alkyl, or 00^- C17 alkyl ; R5 is H or C^C-? alkyl;
R6 and R7 are independently H, C-^^ alkyl, or mono- or di- hydroxyC2-C4 alkyl;
R8 is C-L-C-7 alkyl, or C_-C-j alkenyl;
R9 and R10 are independently H, C_-Cη alkyl, COOR5, CN, CH(OR4)COOR5, Br, CO-thienyl, COC6H4OH(p); Rlχ is NHR4 or OR5;
R12 is C00R5, CH(OR4)CH2OR13 or CH (OCOC-L-^ alkyl) CH2OR5;
R13 is H, COCH2CH2COOH, or COC-L-C-^ alkyl; cyclodextrin complexes of such compound and when R2 or R3 is thienyl substituted with CH2NR6R7, the pharmaceutically acceptable salt of the compound represented thereby.
The polythiophene compounds of this invention are readily formulated into pharmaceutical compositions, also within the scope of this invention, for use in the presently described method for treatment of patients having tumors. In one preferred embodiment of this invention, the pharmaceutical composition comprises an anti-tumor effec- tive amount of a polythiophene compound of the formula:
wherein n is 0, 1 or 2 ,
Rχ is H, CH20H, CHO, CH2NH2, R2 and R3 are independently selected from the group consisting of 2-thienyl, 3-thienyl, mono- or di- substituted 2-thienyl, or mono- or di- substituted 3- thienyl, wherein the thienyl substituents are selected from the group consisting of cyano, chloro, bromo, iodo, C1-C7 alkyl or haloalkyl, C-^-C-j alkenyl or haloalkenyl, C^C^ alkanoyloxy methyl, CH2OR4, C0R5, CH2NR6R7, CH(OR4)R8, CH=CR9R10, CH=NRll7 CH2SC(NH)NH2 and C≡CR12 wherein
R4 is H, CO(CH2)2C02H, (CH2)2OCH3, or COC1-C17 alkyl; R5 is H or C±-Cη alkyl; R6 and R7 are independently H, C1-C4 alkyl, or mono- or di- hydroxyC2-C4 alkyl;
R8 is C1-C7 alkyl, or ^-Cy alkenyl;
R9 and R10 are independently H, C1-C7 alkyl, COOR5, CN, CH(OR4)COOR5, Br, CO-thienyl, or COC6H4OH(p) ; Rχι is NHR4 or OR5;
R12 is C00R5, CH(OR4)CH2OR13 or CH(0C0C1-C4 alkyl) CH2OR5;
R13 is H, COCH2CH2COOH, or C0C1-C17 alkyl; cyclodextrin complexes of such compound and when R2 or R3 is thienyl substituted with CH2NR6R7, the pharmaceutically acceptable salt of the compound represented thereby; with the proviso, that when Rx is H, R2 is selected from the group consisting of 2-thienyl, 3-thienyl, mono- or di- substituted 2-thienyl, or mono- or di- substituted 3-
thienyl, and R3 is selected from the group consisting of 3- thienyl, mono- or di- substituted 2-thienyl, or mono- or di- substituted 3-thienyl, and a pharmaceutically acceptable carrier.
Another pharmaceutical composition within the scope of this invention comprises an anti-tumor effective amount of compound of the formula:
wherein n is 0, l or 2 ,
Rχ is H, CH20H, CHO, CH2NH2,
R2 is selected from the group consisting of 2-thienyl, 3-thienyl, mono- or di- substituted 2-thienyl, or mono- or di- substituted 3-thienyl, and R3 is selected from the group consisting of 3-thienyl, mono- or di- substituted 3- thienyl, di- substituted 2-thienyl wherein the thienyl substituents are selected from the group consisting of cyano, chloro, bromo, iodo, Cι~Cη alkyl or haloalkyl, C-^C-y alkenyl or haloalkenyl, C1-C4 alkanoyloxy methyl, CH2OR4, COR5, CH2NR6R7, CH(OR4)R8, CH=CR9R10, CH=NR12, CH2SC(NH)NH2 and C≡CR12 wherein
R4 is H, CO(CH2)2C02H, (CH2)2OCH3, C1-C4 alkyl or 00^- C_η alkyl;
R5 is H or Cι~Cη alkyl;
R6 and R7 are independently H, C-^-C^ alkyl, or mono- or di- hydroxyC2-C4 alkyl;
R8 is C;L-C7 alkyl, or C -Cη alkenyl;
R9 and R10 are independently H, C_-Cη alkyl, COOR5, CN, CH(OR4)COOR5, Br, CO-thienyl, or COC6H4OH(p) ;
Rlχ is NHR4 or OR5;
R12 is COOR5, CH(OR4)CH2OR13 or
alkyl) CH2OR5;
R13 is H, COCH2CH2COOH, or COC^C-^ alkyl; cyclodextrin complexes of such compound and when R2 or R3 is thienyl substituted with CH2NR6R7, the pharmaceutically acceptable salt of the compound represented thereby, and a pharmaceutically acceptable carrier. The present compounds are readily prepared using art- recognized chemical-synthesis procedures as exemplified hereinbelow. The art is replete with descriptions of the chemistry and synthesis of thiophene and polythiophene compounds. Tables 1, 2, 3 and 4 hereinbelow show several polythiophene compounds that have been tested at the National Cancer Institute. The growth inhibition profiles of several polythiophenes are shown in Tables 5, 6 and 7. The unusually strong activities against solid tumors are predictive of significant therapeutic potency for the treatment of cancer.
Table 1 Compounds registered and tested by NCI
NSC Code R"
645279 CH2OH H
649652 CH2OTs H
203017 COCH3 COCH3
649653 I I
649654 CH=CBr2 H
649656 CH=CHCOTh H
649657 CH=CHCOC6H4OH(p) H
649658 CH2NHC6H5 H
649659 CH=NCH2CH (OH) CH2OH H
647070 CH=C(CN)COOH H
645276 C≡CCH(OH)CH2OH H
645277 C≡CCH(OAc)CH2OH H
646271 CH=N-OH (syn) H
646655 CH=N-OH (anti) H
647073 CHO CH2OH
647074 CHO C7H15
647450 CH2OH C7H15
647451 COC6H13 H
647452 CH2OH CH2OH
647453 CHO CH2OAc
Table 1 Continued
n = 0
NSC Code R' R"
652869 CH2OCO(CH2)2C02H CHO 542870 CH2OCO(CH2)2C02H CH2OCO(CH2)2C02H
THP: tetrahydropyranyl Ac: actyl TS: tosyl Et: ethyl TH: thienyl
Table 2 Compounds registered and tested by NCI
n = 1
NSC Code R"
637393 CHO H
637394 CHO CHO
637388 CH2OH H
645278 CH20Ac H
639392 CH2OEt H
659566 CH(OH)CH3 H
659567 COCH3 H
637389 CN H
637390 CN CN
637391 CH=CHCOOH H
637392 CH=C(COOH)2 H
646267 CH=NNHC6H5 H
646268 CH=N-OH H
660642 CH2SC(NH2) = NH H
646269 C≡CC02Et H
646270 CH2OH CH2OH
646272 CH20(CH2)2OCH3 H
647072 CH2OH CH3
647454 CH3 H
647455 CHO CH2OH
649662 COC2H5 H
649663 CH(OH)C2H5 H
651690 CH2OCO(CH2)2C02H H
Table 2 Continued
n = 1
NSC Code R' R"
652866 CH2NH2 H
660645 CH2NH3 tartarate H
656898 CH2NH2 CH2OH
658110 CH2NH2 CH2NH2
659562 CH2NHCH3 H
658466 CH2NHCH2CH (OH) CH2OH H
659563 CH2N(CH3)2 H
659561 CH2N(C2H5)3C1 H
659564 CH2N(CH3)2 CH2N(CH3)2
659565 CH2N(CH3)2 CH2OH
Table 3 Compounds registered and tested by NCI
n = 2
NSC Code R' R"
645273 CHO H 645274 CH2OH H
Table 4 Compounds registered and tested by NCI
NSC Code S-r*m~
658880
653877
Table 4 Continued
666165
Table 4 Continued
Table 5: The growth inhibition of the human cancer cell lines by polythiophene Log10 GI50 (M)
Compd.
Cell Line
Lung Cancer
A549/ATCC -5. .05 -5.18 -4.49
EKVX -4.61 -4.26
HOP-18 -4.98 -4.65 -5.63
HOP-62 -5.01 -4.62
NCI-H23 -4.15 -4.71 -4.26
NCI-H226 -6.50 -6.93 -6.49 -7.61
NCI-H322M -4. .52 -4.53 -4.71 -4.37
NCI-H460 -5.87 -6.31 -5.82 -4.86
NCI-H522 -4.02 -4.88 -4.49
LXPL-529 -6.54 <-8.00 <-8.00 <-8.00
Colon Cancer
COLO-205 -5.44 -6.04 -6.36 -5.27
DLD-1 -6.50 -5.35 <-8.00 -5.10
HCC-2998 -4.44 -4.61 -4.75
HCT-116 -5.34 -6.53 -7.20
HCT-15 -4.45 -4.30 -4.62
HT29 -5.07 -4.52 -4.61
KM20L2 -5.80 -6.61 -6.88 -6.31
SW-620 -5.33 -6.27
CNS Cancer
SF-268 -4.61 -4.06
SF-295 -4.42 -4.47 -4.74 -4.16
SNB-75 -6.41 <-8.00 -4.50
SNB-19 -4.73
Table 5 Continued
Compd .
Cell Line
CNS Cancer
U251 -6.34 -6.83 <-8.00
XP-498 -5.43
Melanoma
LOX IMVI -4.62
MALME-3M -4.49 -4.10
M-14 -4.40 -4.20
SK-MEL-2 -4.14 -4.51
SK-MEL-28 -4.05
UACC-257 -6.03 -6.99 -7.03 -7.33
UACC-62 < -8.00 -4.77 -8.00
Ovarian Cancer
IGROV-1 -7.37 -5.30 -7.22
OVCAR-3 -5.63 -7.59 -7.52
OVCAR-4 -4.51
OVCAR-5 -4.89 -6.65 -4.58 -6.86
OVCAR-8 -4.28 -4.27
SK-OV-3 -4.04 -4.06
Renal Cancer
786-0 -4.49 -4.73 -4.36
A-498 < -8.00 -7.36 -7.36
ACHN -4.75 -4.29
CAKI-1 -6.65 -7.56 -7.74 -7.86
RXF-393 -4.24 -7.50 -4.74 -4.78
RXF-631 -6.09 -7.55 <-8.00
SN12C -4.54 -4.32
Table 5 Continued
Compd.
Cell Line
Renal Cancer
TK-10 -6.63 -6.98 -6.92 -6.28
UO-31 -4.41 -4.73 -4.38
GI 50' molar concentration required for 50% growth inhibition
Table 6: The growth inhibition of the human cancer cell lines by chemically modified a-polythiophene derivatives
Log10 GI50 M
Compd.
Cell Line
Lung Cancer A549/ATCC -5.91
HOP-18 -5.51
HOP-62 -5.52
HOP-92 -4.09
NCI-H226 -7.60 -7.88 -5.76 -5.23 NCI-H322M -5.77
NCI-H460 -6.29 -7.80 -5.62
LXPL-529 -6.33 < -8.00 -5.95 -5.98
Colon Cancer COLO-205 -6.22 -6.81
DLD-1 -4.74
HCT-116 -5.27 -7.82 -4.74
HCT-15 -4.19
HT29 -5.04 KM20L2 -6.15 -6.84 -4.39
KM12 -4.35
SW-620 -5.04 -7.17
HCC-2998 -6.40 -5.74
CNS Cancer
SNB-78 -4.44
SNB-75 -4.43 -4.14
SNB-19 -4.72 -4.97
U251 -7.73 -6.09 XP-498 -7.52 -4.96
Table 6 Continued
Compd .
Cell Line
CNS Cancer SF-295 -4.43
Melanoma UACC-257 -6.00 -7.8^5.72 -4.97 UACC-62 -6.36 <-8.-θ€).46
Ovarian Cancer
IGROV-1 -6.57 <-8.-ΘS.15 -5.95
OVCAR-3 -5.70 <-8.00
OVCAR-4 -4.46
OVCAR-5 -6.06 -7.S24.68
OVCAR-8 -5.23 -4.10
SK-OV-3 -5.80 -5.38
Renal Cancer
A-498 •7.71 <-8.-ΘB.93
CAKI-1 -6.63 <-8.-ΘB.88 -6.21
RXF-631 <-8.00 ■4.03-4.96
TK-10257 -6.29 -7.845.29 -6.05
RXF-393 •7.05
GI 50' Concentration required for 50% growth inhibition
Table 7: Growth inhibition of the human solid cancer cell lines by polythiophenes LOG10 GI50 (M)
Compd.
Cell Line
Lung Cancer HOP-62 -4.69 ■4.70 HOP-92 -4.41 -5.03 NCI-H23 -4.62 > 5.00 -4.41 NCI-H226 -7.85 -6.59 NCI-H322M -4.79 -5.37 NCI-H460 -4.60 -7.41 -5.25 NCI-H522 -4.47
Colon Cancer
COLO-205 ■6.04 -6.72 -5.23 HCC-2998 ■6.01 -5.23 ■6.50
HCT-116 ■6.44 -6.97
HCT-15 -4.23 > -5.00 ■4.55
HT29 -4.8-66.63 -4.73
KM12 -4 0β5.00 -4.78 SW-620 -4.32 -4.39
CNS Cancer SF-268 4.27 > -5.00 SF-295 4.45 > -5.00 -4.47 SF-539 > -5.00 SNB-19 4.48 > -5.00 SNB-75 4.51 -5.70 U251 -4.9^75.25 -4.16
Table 7 Continued
Compd.
Cell Line
Melanoma
MALME-3M 4.41 > -5.00 -4.53
M14 -4> 3-75.00 -4.29
SK-MEL-28 4.44 > -5.00 -4.40
SK-MEL-5 4.38 > -5.00 > -5.00
UACC-257 6.72 -7.42
UACC-62 -6.74
L0X1MV1 > -5.00
SK-MEL-2 > -5.00
Ovarian Cancer
IGROV1 -6.66 -6.84 -6.64
OVCAR-3 -6.80 -7.16
OVCAR-4 -4.60 -6.52
OVCAR-5 -6.38 -6.90
OVCAR-8 -4.24 > -5.00 -4.30
Renal Cancer
786-0 -4.24 -4.28
A498 -6.947.80
CAKI-1 -7.64 -7.60
RXF-393 -4.69 > -5.00 -5.06
TK-10 -6.69 -7.10 -4.68
UO-31 -4.19
SN12C > -5.00 -4.33
ACHN > -5.00 ■4.25
Prostate Cancer PC-3 -4 2-95.00 -4.31
Table 7 Continued
Compd.
Cell Line
Prostate Cancer
DU-145 -4.18 > -5.00 -4.26
Breast Cancer
MCF7 -6.&96.86 -6.75
MCF7/ADR- > -5.00 -4.24
RES
MDA-MB- -4.55 > -5.00
231/ATCC
MDA-N -6.30 -5.02 -5.27
T-47D -6.47 -6.65 -6.37
HS 578T -5. .11 -4.28
MDA-MB- -5. .36 -4.82
435
BT-549 > - -5.00 -4.08
The cytotoxic activity of the present polythiophene compounds have been measured utilizing three different assays or screens. The first screen measures the cytotoxicity against a panel of sixty different human tumor cell lines. This assay provides data regarding the general cytotoxicity of an individual compound. In particular this type of assay is useful in identifying compounds which have enhanced cytotoxic activity against slow growing tumors as compared to faster growing tumor cells such as leukemia tumor cell lines. The identification of such compounds is critical since previously identified antitumor agents have low cytotoxic activity against slower growing tumors. The specificity of a compound for a limited number of tumor cell lines also indicates that such a compound will likely be less cytotoxic to normal cells. The specificity of a cytotoxic compound for tumor cell lines relative to normal cells is an important characteristic of an effective antitumor agent. Antitumor cytotoxicity data for the National Cancer
Institute human tumor cell panels can also be expressed in a graphic pattern (mean graph) to display differential cell growth inhibition (K.D. Paull, R.H. Shoemaker, L. Hodes, A. Monks, D.A. Scudiero, L. Rubinstein, J. Plowman and M.R. Boyd, J . Natl . Cancer Inst . , 81, 1088, 1989.) In the mean graph, the arithmetic mean of the logarithm of the GI50 (50% growth inhibition) , TGI (total growth inhibition) or LC50 (50% lethal concentration) values is used as an anchor point. Relative cytotoxicity is displayed by projecting bars to the right or left of the mean, depending on whether cell sensitivity to a test compound is more or less than average. The length of a bar is indicative of differential cytotoxicity against a specific type of tumor cells or tumor panels. In a second assay, the cytotoxic selectivity is assessed
by comparing compound cytotoxicity against transformed cells and normal cells. IC50 values were compared between treated TBE cells (ras-transformed human bronchial epithelial cells) and NHBE cells (Normal human bronchial epithelial cells) . Cytotoxic effects on normal human bronchial epithelial cells (NMBE) and ras-transformed human bronchial epithelial cells (TBE) were measured by the cell count (cell number) using Coulter Z.F. counter (Hialeah, FL) carried out at Purdue University. The result is expressed as GI50, concentration of drug at which cell numbers are reduced to 50% of control cell culture (T.C.K. Chan, C.-j. Chang, N.M. Koonchanok and R.L. Geahlen, Biochem . Biophys . Res . Commun . , 193, 1152, 1993). The data presented in Table 8 illustrates that polythiophenes generally exhibit greater cytotoxicity for transformed human cells in comparison to the normal human cells.
The antitumor cytotoxicity of the thiophene compounds tested in the first two in vitro assays was measured by a microculture assay using either 3- (4 , 5-dimethylthiazol-2-yl) -2 , 5-diphenyltetrazolium bromide (MTT) or sulforhodamine B (SRB) . [M.R. Boyd in "Principles and Practices of Oncology," V.T. DeVita, Jr.,
Table 8: Selective cytotoxicity against ras-oncogene transformed human bronchial epithelial cells
GIJ0(ug/ml)
CHO
637393 C- -U- 0.03 0.2
-CH20H
£37388 LΓ 0.02 3.0
OHC-
637394 3-0- CHO
0.01 0-2
HOH-C- m -CHjOH
646270 0.02 1.0
HOEjC- -CHO
647073 0.05 0.08
H0CH ^2 CH20H
647452 0.03 0.6
HOH-.C- . »— CH»NH.
656898 0.02 3.0
H.SiH.C — "s. ^. 1 ^e ^-CH.NHι 5
658110 ^C^ * 4.0 10
658879
0.004 6.2
Table 8 Continued
S. Hellman and S.A. Rosenberg (Eds.), Vol. 3, PPO Updates, Number 10, 1989.] This assay has an advantage over in vivo assay in that results are obtained within a week as opposed to several months. The assay was carried out in 96-well microtiter plates. The MTT assay is based on the production of a dark blue formazan product by dehydrogenase in the mitochondria of live tumor cells after exposure to drug for 6 days [M.C. Alley, D.A. Scudiero, A. Monks, M.L. Hursey, M.J. Czerwinski, D.L. Fine, B.J. Abbott, J.G. Mayo, R.H. Shoemaker and M.R. Boyd, Cancer Res . , 48, 589, 1988.] Thus, only live cells are stained and can be measured at 570 nm. The SRB assay is based on the binding of the anionic group to the basic amino acid residues of cellular proteins after exposure of tumor cells to drug for 2 days [P. Skehan, R. Storeng, D. Scudiero, A. Monks, J. McMahon, D. Vistica, J.T. Warren, H. Bohesch, S. Kenney and M.R. Boyd, J. Nat . Cancer Inst . , 82, 1107, 1990.] Thus, the total protein (viability) can be measured at 564 nm. Antitumor cytotoxicity is reported as GI50, effect drug dose at which cell growth is retarded to 50% of control culture of tumor cells. The active compounds are defined as those compounds having GI50 values that are less than 10-4 M or 10 μg/ml.
Antitumoral activity of the present polythiophene compounds has been confirmed by in vivo animal test data. The in vivo data was derived from experiments in which human tumors are transplanted into immune deficient mice and allowed to grow for two days prior to treatment with a polythiophene composition of this invention. See Example 48 and accompanying Tables 9 and 10. Data obtained from studies using heterotransplanted tumors in immune deficient mice are recognized as well-correlated with the effectiveness of these agents in clinical studies (Giovanella, B.C. et al. Cancer 52(7): 1146 (1983).
The present invention further provides pharmaceutical formulations comprising an effective amount of a polythiophene compound for treating a patient having a tumor. As used herein, an effective amount of the polythiophene compound is defined as the amount of the compound which, upon administration to a patient, inhibits growth of tumor cells, kills malignant cells, reduces the volume or size of the tumors or eliminates the tumor entirely in the treated patient. The effective amount to be administered to a patient is typically based on body surface area, patient weight, and patient condition. The interrelationship of dosages for animals and humans (based on milligrams per meter squared of body surface) is described by Freireich, E.J., et al., Cancer Chemother. Rep. , 50 (4): 219 (1966). Body surface area may be approximately determined from patient height and weight (see e.g., Scientific Tables, Geigy Pharmaceuticals, Ardley, New York, pages 537-538 (1970)). An effective amount of the polythiophene compounds in the present invention can range from about 5 mg/kg. to about
500 mg/kg, more preferably from about 5 mg/kg to about 250 mg/kg, and most preferably about 5 to about 150 mg/kg.
Effective doses will also vary, as recognized by those skilled in the art, dependant on route of administration, excipient usage and the possibility of co-usage with other therapeutic treatments including other anti-tumor agents, and radiation therapy.
The pharmaceutical formulation may be administered via the parenteral route, including subcutaneously, intraperitoneally, intramuscularly and intravenously. Examples of parenteral dosage forms include aqueous solutions of the active agent, in a isotonic saline, 5% glucose or other well-known pharmaceutically acceptable liquid carrier. In one preferred aspect of the present embodiment, the polythiophene compound is dissolved in a
saline solution containing 5% of dimethyl sulfoxide and 10% Cremphor EL (Sigma Chemical Company) . Additional solubilizing agents such as cyclodextrins, which form specific, more soluble complexes with the present polythiophene compounds, or other solubilizing agents well- known to those familiar with the art, can be utilized as pharmaceutical excipients for delivery of the polythiophene compounds.
The present compound can also be formulated into dosage forms for other routes of administration utilizing well- known methods. The pharmaceutical compositions can be formulated, for example, in dosage forms for oral administration in a capsule, a gel seal or a tablet. Capsules may comprise any well-known pharmaceutically acceptable material such as gelatin or cellulose derivatives. Tablets may be formulated in accordance with conventional procedure by compressing mixtures of the active polythiopene and solid carriers, and lubricants well-known to those familiar with the art. Examples of solid carriers include starch, sugar, bentonite. The compounds of the present invention can also be administered in a form of a hard shell tablet or capsule containing, for example, lactose or mannitol as a binder and a conventional fillers and tableting agents. The following examples are provided to illustrate various embodiments of Applicants' invention, and are not intended to in any way limit the scope of the invention as set forth in this specification and appended claims.
Example 1
Synthesis of 5-formyl-5'-heptyl-2.2 ' -bithiophene (NSC code # 647074)
Dimethyl formamide (DMF) (8 ml) was stirred at 0°C for 10 minutes, P0C13 (1 ml) was added and then stirred for 1 hours. 5-Hepty1-2, 2 ' -bithiophene (0.5 g) dissolved in
dimethyl formamide (5 ml) was added and stirred at room temperature for half an hour at room temperature, then the temperature was raised to 60°C and was further stirred for 4 hours. The reaction solution was then extracted with dichloromethane, neutralized with sodium acetate, washed with water to neutrality, dried, concentrated and separated by silica gel chromatography eluted with ethyl acetate/n-hexane (1/15) . Light yellowish oily product (0.86 g, 86%) was obtained. Spectral Data: λH NMR (CDC13) , S value
9.81 (s, 1H, -CHO), 6.71-7.62 (m, 4H, protons of thiophene)
2.79 (t, 2H, -CH2) , 0.86 (t, 3H, CH3) IR (neat) : cm"1
2910 (CH) , 1665 (C=0) Mass spectrum, m/e (relative intensity)
264 (M+, 44), 206 (100)
Preparation of 5-heptyl-2 , 2 ' -bithiophene
To a solution of 5- (heptan-1-one) -2, 2 '-bithiophene (2.0 g, 7.19 mmole) in dioxane (20ml), a mixture of hydrochloric acid, dioxane and glacial acetic acid (15:20:15) was added. Excess of freshly prepared zinc amalgam was then added and stirred at room temperature for 2 hours. The solution mixture was then extracted with ether, neutralized with 10% sodium hydroxide aqueous solution, washed with water to neutrality, dried, concentrated and separated by silica gel chromatography eluted with n-hexane/ethyl acetate (1:20). Oily product 0.91g (48%) was obtained. Spectral Data: 1H NMR (CDCI3) , δ value
6.65-7.24 (m, 5H, protons of thiophene), 1.67-1.23 (m, 2H, CHn) , 0.87 (t, 3H, CH3)
IR (neat) : cm"1
2910 (CH) Mass spectrum, (m/e) (relative intensity) 264 (M+, 24), 179 (100)
Preparation of 5- (heptan-1-one) -2,2' -bithiophene To a solution of 2 , 2 ' -bithiophene (0.57 g, 3.43 mmole) (Aldrich Chem. Co., Milwaukee, WI) in benzene (10 ml) was added proper amount of phosphorous pentaoxide and was stirred at room temperature until the solution was homogeneous. Heptanoic acid (0.7 g, 5.35 mmole) was dissolved in benzene (10 ml) and added slowly to the reaction mixture. The solution was heated to 70°C for 2 hours. The solution was extracted with ethyl acetate, washed with sodium bicarbonate aqueous solution several times, then washed with water until neutrality. The extract was dried and concentrated. The residue was separated by silica gel chromatography, eluted first with hexane to recover starting material and then with n-hexane/ethyl acetate (10:1). Light yellowish crystalline product 0.28g (30%) was obtained, melting point 85°C. Spectral Data: XH NMR (CDC13) , δ value
7.55-7.01 (m, 5H, protons of thiophene), 1.75-1.20 (m, 8H, CH2) ,
0.85 (t, 3H, CH3) IR (KBr) : cm"1
1645 (C=0) Mass spectrum: m/e (relative intensity) 278 (M+, 20), 208 (40), 193 (51), 179 (100)
Example 2
Synthesis of (5-heptyl-5' -hydroxymethyl) -2.2 '-bithiophene (NSC code # 647450) 5-Formyl-5'-heptyl-2, 2 '-bithiophene (0.4 g) was dissolved
in tetrahydrofuran (THF) (15 ml) and stirred at O'C for 10 minutes. NaBH4 (0.1 g) was added at room temperature and stirred for 2 hours. Then the solution was extracted with ethyl acetate (100 ml) . The extract was washed with water, then dried and concentrated. The solid product was thus obtained and further recrystallized from ethyl acetate/n-hexane mixture. Light yellowish solid product (0.21 g, 52%) was obtained and the melting point of the product was 59 °C. Spectral Data:
1H NMR (CDC13) , δ value
6.64-6.96 (m, 4H, protons of thiophene) 4.77-4.78 (m, 2H, 0CH2) , 2.75 (t, 2H, CH2) 1.23-1.76 (m, 2H, CH2) , 0.87 (t, 3H, CH3) IR (KBr) : cm"1
3250 (OH) , 1070 (C-OH) Mass spectrum, m/e (relative intensity) 294 (M+, 59), 209 (100)
Preparation of 5-formyl-2 f 2 ' -bithiophene
To dimethyl formamide (250 ml) was added phosphoryl chloride (50.2 ml) with quick stirring. 2, 2 '-Bithiophene (83 g) in dimethyl formamide (200 ml) was then added and stirred at -10°C for 30 minutes. Then the temperature was raised to 40°C and was further stirred for 20 hours. The reaction mixture was then poured into crushed ice and stirred for 30 minutes. Sodium hydroxide aqueous solution (10%, 600 ml) was added and the solution was extracted with chloroform. The organic layer was washed with water, dried over anhydrous magnesium sulfate, concentrated and separated by silica gel chromatography. Product 90 g was obtained, melting point 56-57°C. Spectral Data: 1H NMR (CDC13) , δ value 9.70 (s, 1H) , 7.60-7.47 (m, 1H) , 7.30-7.10 (m, 3H) ,
7.06-6.90 (m, 1H)
Example 3
Synthesis of 5- (1-hvdroxypropyl) -2.2 '-bithiophene 5-Formy1-2, 2 '-bithiophene (3 g) was dissolved in THF (50 ml) and ethyl-magnesium bromide Grignard reagent (9.3 ml) was added dropwisely under nitrogen gas atmosphere in ice bath and stirred for 1 hour. The mixture was stirred for 1 hr. and then continuously stirred at room temperature. The reaction was monitored by thin layer chromatography. After the reaction was completed, water (30 ml) and ethyl acetate (200 ml) were added to the mixture and extracted and purified by column chromatography, eluted with ethyl acetate/n-hexane (1/9) . Light yellowish product was thus obtained.
Spectral Data:
1H NMR (CDC13) , δ value
7.16-6.63 (m, 5H, protons of thiophene), 4.78-4.73 (t, 1H, -CH(OH)CH2CH3) 1.92-1.79 (m, 2H, -CH2CH3) , 0.98-0.90 (t, 3H, -CH3) IR (NaCl) : cm"1
3400 (OH) , 2950 (CH)
Example 4 Synthesis of 5- (3.4-dihydroxy-l-butenyl) -2 , 2 ' -bithiophene
5- (3-Oxo-but-l-en-4-al) -bithiophene (0.5 g) and NaBH4 (0.2 g) were dissolved in tetrahydrofuran (10 ml) and stirred at room temperature for 2 hours. The reaction solution was added with ethyl acetate (200 ml) and distilled water. The extract was washed with water and dried over anhydrous magnesium sulfate. After concentration, the product was separated by column chromatography, eluted with ethyl acetate/n-hexane (3/7) . Light yellowish crystals were thus obtained and melting point thereof was 96-98 °C.
Spectral Data:
Xn NMR (400 MHZ, CDCl3) , <5 value
3.60-3.74 (dd, 2H, -CH2OH) , 4.40 (m, 1H, -CH(OH)), 5.98-6.06 (dd, 1H, C=CH-) , 7.20-7.26 (d, 1H, -CH=C) 6.86-7.17 (m, 5H, protons of thiophene)
IR (KBr) : cm"1
3326, 3076, 1462, 1423, 1122, 960, 790, 688
Mass spectrum (12 ev) , m/e (relative intensity)
252 (M+, 91), 233(30), 221(100), 204(24), 176(15)
Preparation of 5-f3-oxo-but-l-en-4-al) -2.2' -bithiophene
5- (4 , 4-Dimethoxy-3-oxo-l-butenyl) -2,2' -bithiophene was dissolved in ethanol (40 ml) . Hydrochloric acid (3 N, 20 ml) was added and refluxed for 4 hours. The reaction mixture was extracted with ethyl acetate (400 ml) . The extract was washed with water and sodium bicarbonate aqueous solution, dried, concentrated and separated by silica gel chromatography. Dark orange oily product was obtained.
Preparation of 5- (4 ,4-dimethoxy-3-hvdroxy-l-butenyl) - 2,2' -bithiophene
To a solution of 5- (4, 4-dimethoxy-3-oxo-l-butenyl) - 2 , 2 ' -bithiophene (50 mg) in tetrahydrofuran (2.5 ml) was added sodium borohydride (10 mg) . The reaction mixture was stirred at room temperature for 1 hour. Ethyl acetate and water was added for partition. The organic layer was dried over anhydrous magnesium sulfate, concentrated and separated by silica gel chromatography. Light greenish oily product was obtained. Spectral Data: 13C NMR (CDC13) , δ value
140.91, 137.49, 136.25, 127.87, 127.00, 126.42, 125.04, 124.46,
123.88, 123.71, 71.83, 55.73, 55.11
(neat) : cm-1
3400 (O-H) , 2950 (C-H) , 1070 (C-O)
Preparation of 5- (4 , 4-dimethoxy-3-oxo-l-butenyl) - 2.2'-bithiophene
To a solution of 5-formyl-2, 2 '-bithiophene (4.0 g) in ethanol (120 ml) was added dimethoxymethyl methyl ketone (3 ml) . Potassium hydroxide aqueous solution (50%) was added dropwisely into the solution mixture at 16°C. Color changed from yellowish brown into dark green, then dark brown. Yellow solid was formed during the reaction. Water was added. Solid residue was filtered and washed with water, redissolved in acetone and separated by silica gel chromatography eluted with ethyl acetate/n-hexane (1:9). Yellowish crystals 1.88 g were obtained, melting point 74°C.
Spectral Data: λH NMR (CDC13) , δ value 7.82 (d, 1H, -CH=CH-) , 7.27-7.03 (m, 5H, protons of thiophene) ,
6.77 (d, 1H, -CH=CH-) , 3.43 (s, 6H, (OCH3)2) Mass spectrum, m/e
294 (M+) , 219 (M+-CH(OCH3)2)
Example 5 Synthesis of 5-hvdroxymethyl-5"-methyl-α-terthiophene (NSC code # 647072) 5-Formyl-5"-methyl-α-terthiophene (0.2 g) was dissolved in ethanol (50 ml). NaBH4 (0.1 g) was added at room temperature and stirred for 30 minutes. The solution was monitored by thin layer chromatography. After the reaction was completed, 150 ml of ethyl acetate and 50 ml of water were added therein. The ethyl acetate solution was washed with water, dried and then purified by silica gel column
chromatography. Light yellowish crystals were thus obtained and melting point thereof was 126-128°C. The yield was almost quantitative. Spectral Data: XH NMR (CDC13) , δ value
7.09-6.72 (m, 6H, protons of thiophene)
4.87-4.85 (d, 2H, -CH2OH) , 2.54 (s, 3H, -CH3) IR (KBr) : cm"1
3300 (-0H), 2900(C-H), 1450 (conjugative C=C) Mass spectrum, m/e (relative intensity)
292 (M+, 100), 275 (79), 258 (11)
Preparation of 5-formyl-5"-methyl-c.-terthiophene Phosphoryl chloride (1.0 ml) was added slowly to dimethyl formamide (30 ml) at 0°C under nitrogen atmosphere. The mixture was further stirred for 1 hour at 0°C. 5-Methyl- - terthiophene (0.5 g) in dimethyl formamide (5 ml) was added dropwisely into the reaction mixture and stirred at room temperature for 30 minutes. Temperature was raised to 60°C and was further stirred for 2 hours. The reaction was monitored by thin layer chromatography until no starting material was left. The reaction mixture was then poured into potassium carbonate aqueous solution with crushed ice and extracted with ethyl acetate (200 ml) . The extract was washed with water, dried, concentrated and separated by silica gel chromatography, eluted with ethyl acetate/n-hexane (1:4). The product was recrystallized from ethanol to give orange crystals (90% yield) , melting point 158-159°C. Spectral Data: λH NMR (CDC13) , δ value
9.82 (S, 1H, CHO), 7.64-6.66 (m, 6H, protons of thiophene) , 2.47 (s, 3H, CH3) IR (KBr) : cm-1
1670 (conjugated C=0) , 1450 (conjugated C=C) Mass spectrum: m/e (relative intensity) 290 (M+, 100), 257 (9), 217 (7)
Preparation of 5-methyl-α-terthiophene
5-Formyl-α-terthiophene (0.5 g) was dissolved in a solution mixture of hydrochloric acid, dioxane and glacial acetic acid (1:2:1) (50 ml). Zinc amalgam (5 g) was added and stirred at room temperature for 3 hours. The reaction was monitored with thin layer chromatography until no starting material was detected, and then extracted with ethyl acetate (200 ml) . The extract was washed with potassium carbonate aqueous solution, dried, concentrated and separated by silica gel chromatography eluted with n-hexane. The product was recrystallized from n-hexane to give light yellowish crystals, melting point 93-94°C, yield 90%.
Spectral Data: λH NMR (CDC13) , δ value 7.19 (m, 7H, protons of thiophene), 2.46 (s, 3H, CH3) IR (KBr) : cm"1
2900 (0-H) , 1430 (conjugated C=C)
Mass spectrum: m/e (relative intensity)
262 (M+, 100), 239 (17), 131 (12)
Preparation of 5-formyl-a-terthiophene and 5.5"-diformyl-α-terthiophene
(1) Phosphoryl chloride (1.0 ml) was added to dimethyl formamide (15 ml) and stirred for few minutes under nitrogen atmosphere. α-Terthiophene (2.48 g) (Aldrich
Chem. Co., Milwaukee, WI) in dimethyl formamide was added slowly and then heated to 70°C. The temperature was then raised to 110°C and further stirred for 2.5 hours. Cooled to room temperature and extracted with chloroform (100 ml) . The extract was dried, concentrated and separated by silica
gel chromatography eluted with chloroform/n-hexane (1:4) to give 5-formyl-α-terthiophene (1.94 g, 74.2%), melting point 141-142 °C. Further elution with chloroform/n-hexane/ethyl acetate (38:1:1) gave 5,5"-diformyl-α-terthiophene (0.13 g, 4.3%), melting point 219-220°C. α-Terthiophene (0.13 g) was recovered. Spectral Data: 5-formyl-α-terthiophene λE NMR (CDC13) , δ value 9.86 (s, 1H, CHO), 7.67(d, 1H, J=4Hz) , 7.25 (d, 2H,
J=4Hz) ,
7.21 (d, 2H, J=4Hz) , 7.10 (d, 1H, J=4Hz) , 7.02 (t, 1H,
J=4Hz)
U max: λmax: 400nm IR (KBr) : cm-1
1649 (C=0) , 2930 (C-H)
Mass spectrum: m/e
276 (M+) 5, 5"-diformyl-α-terthiophene
XH NMR (CDC13) , δ value
9.86 (s, 2H, CHO), 7.67 (d, 2H, J=4Hz) , 7.30 (s, 2H) ,
7.27 (d, 2H, J=4HZ) UVmax: ^max: 400nm IR (KBr) : cm-1
1649 (C=0)
Mass spectrum: m/e
304 (M+) (2) To a solution of 5-iodo-2-form lthiophene (1.0 g) in acetonitrile (200 ml) was added 2 , 2 ' -bithiophene (0.7 g) under nitrogen and irradiated with 100W mercury lamp for 12 hours. The reaction was monitored with thin layer chromatography until no further product was produced. The solvent was removed and extracted with dichloromethane.
The extract was dried, concentrated and separated by silica gel chromatography eluted first with ethyl acetate/n-hexane (1:9) to recover starting material, and then with ethyl acetate/n-hexane (3:7) to obtained 5-formyl-α-terthiophene.
Example 6 Synthesis of 5-(propan-l-ol) - -terthiophene (NSC code # 649663)
(1) 5-(Propan-l-one) - -terthiophene (0.6 g) was dissolved in ethanol (150 ml) and heated to dissolve completely.
NaBH4 (0.1 g) was added at room temperature and stirred for 3 hours. The solution was monitored by thin layer chromatography. After the reaction was completed, 50 ml of water was added and the ethanol was removed under reduced pressure. Yellowish green solid was thus obtained and melted at 89-90°C. The yield was almost quantitative. Spectral Data: XH NMR (CDC13) , δ value
7.20-6.84 (m, 7H, protons of thiophene) 4.80-4.77 (t, 1H, -CH (OH) -CH2CH3) , 1.93-1.80 (m, 2H, -CH2CH3) , 0.99-0.94 (t, 3H, -CH2CH3) IR (KBr) : cm"1
3400 (-OH), 2900 (-CH), 1450 (conjugative C=C) Mass spectrum, m/e (relative intensity) 304 (M+, 58), 277 (100)
(2) 5-Formyl- -terthiophene (3.5 g) was dissolved in anhydrous THF (200 ml) under nitrogen stream. Ethyl Grignard reagent (7.9 ml) was dropped in slowly in ice bath and stirred at 0°C for l hour. The reaction mixture was then heated to 70°C in oil bath for 4 hours. The solution was monitored by thin layer chromatography. After the reaction was completed, 50 ml of water and 300 ml of ethyl acetate were added to extract the crude product, which was then purified by column chromatography, eluted with ethyl acetate/n-hexane (1/9) . Yellow solid was then obtained and
recrystallized to give granulate crystals. The melting point of the product was 89-90°C and the yield was about 70%.
Preparation of 5-fpropan-l-one) - -terthiophene
To a solution of -terthiophene (5.0g) in benzene (250 ml) was added phosphorous pentaoxide (3.1g). Propanoic acid (1.6 g) was then added slowly at room temperature. The reaction mixture was heated to reflux and the reaction was monitored with thin layer chromatography. A little more phosphorous pentaoxide was added to complete the reaction. Potassium carbonate aqueous solution was added and extracted with ethyl acetate. The extract was dried, concentrated and separated by silica gel chromatography, eluted with ethyl acetate/n-hexane (1:19) to give yellow solid product, which was recrystallized from ethyl acetate/n-hexane (1:19) to give yellowish crystals (20% yield) , melting point 136-137°C. Spectral Data: XH NMR (CDC13) , <S value
7.58-7.00 (m, 7H, protons of thiophene), 2.89 (q, 2H, CH2),
1.22 (t, 3H, CH3) IR (KBr) : cm"1 2900 (C-H) , 1650 (conjugated C=0) , 1440 (conjugated C=C) Mass spectrum: m/e (relative intensity)
304 (M+,73), 275 (100), 247 (21), 203 (59)
Example 7 Synthesis of 5-formyl-5"-(prop-l-enyl) -α-terthiophene
P0C13 (2 ml) was added into dimethyl formamide (30 ml) slowly under nitrogen gas atmosphere in ice bath and stirred for 1 hour. Dimethyl formamide (20 ml) solution of 5- (prop-1-enyl) -terthiophene (0.8 g) was dropped in slowly. The mixture was stirred for half an hour at room
temperature, then the temperature was raised to 60°C and was further stirred for 2 hours. The solution was monitored by thin layer chromatography. After the reaction was completed, the reaction solution was poured into sodium carbonate ice water solution. Then the solution was extracted with 300 ml of ethyl acetate. After drying and evaporation of the solvent residual solid was purified by column chromatography, eluted with ethyl acetate/n-hexane (1/9) . Orange solid product was obtained and the melting point of the product was 146-148°C. The yield was about 70%.
Spectral Data: XH NMR (CDC13) , δ value
9.50 (s, 1H, -CHO), 7.65-6.74 (m, 6H, protons of thiophene)
6.47-6.43 (dd, 1H, -CH=CHCH3) , 6.11-6.02 (m, 1H,
-CH=CHCH3)
1.86-1.84 (d, 3H, CH3) IR (KBr) : cm"1 2900 (CH), 1660(conjugative C=0) , 1440 (conjugative C=C) Mass spectrum, m/e (relative intensity)
316 (M+, 100) , 149 (58)
Preparation of 5-(prop-l-enyl) -α-terthiophene 5-(Propan-l-ol) -α-terthiophene (0.8 g) was dissolved in a mixture of benzene/methanol (1:1) (100 ml). Hydrochloric acid (2 N, 5 ml) was added at room temperature. Heated to 50°C for 1 hour and monitored with thin layer chromatography until no starting material was left. Ethyl acetate (250 ml) and water was added for partition. The organic layer was dried, concentrated and separated by silica gel chromatography eluted with n-hexane to give desired product. Spectral Data: 2H NMR (CDC13) , 6 value
7.19-6.72 ( , 7H, protons of thiophene), 6.45 (d, 1H, CH=CHCH3) ,
6.08-5.99 (m, 1H, CH=CHCH3) , 1.85 (d, 3H, CH=CHCH3) IR (KBr) : cm"1 2850 (C-H) , 1430 (conjugated C=C)
Example 8
Synthesis of 5-hydroxymethγl-5"-fprop-l-enyl) -α-terthiophene 5-(Prop-l-enyl) -5"-formyl-α-terthiophene (0.4 g) was dissolved in ethanol (50 ml). NaBH4 (0.1 g) was added at room temperature and stirred for 2 hours. The solution was monitored by thin layer chromatography. After the reaction was completed, water (50 ml) was added and the ethanol was removed under reduced pressure. Then the solid precipitate was extracted with 200 ml of ethyl acetate. The concentrated residual solid was purified by column chromatography, eluted with ethyl acetate/n-hexane (3/7) . Yellowish solid product was obtained and melting point thereof was 132-134 °C. The yield was nearly 100%. Spectral Data: XH NMR (CDC13) , δ value
7.20-6.60 (m, 6H, protons of thiophene) 6.46-6.42 (dd, 1H, -CH=CH-CH3) , 6.06-6.01 (m, 1H, -CH=CH-CH3)
4.79-4.78 (d, 2H, -CH2OH) , 1.85-1.84 (d, 3H, -CH3) IR (KBr) : cm"1
3400 (OH) , 2900 (CH) , 1440 (conjugative C=C) Mass spectrum, m/e (relative intensity) 318 (M+, 100), 301 (26), 261 (40)
Example 9
Synthesis of 5-ethyl-α-terthienylmethyl ether
(1) 5-Formyl-α-terthiophene (0.3 g) was dissolved in ethanol (20 ml) by stirring at room temperature. To the
solution, 0.04 g of NaBH4 was slowly added. After the solution became clear in about 20 minutes, diluted hydrochloric acid was slowly added until bubbling stopped. The stirring was continued for about 12 hours, followed by chloroform extraction and silica gel column chromatography eluted with ethyl acetate/n-hexane (1/19) . The product was recrystallized from chloroform/ethyl acetate mixture to give light yellowish platelet crystals (melting point 76-77°C). The yield was about 41%. (2) The yield could be increased to 85% or higher by substituting absolute ethanol for alcohol and concentrated hydrochloric acid for diluted hydrochloric acid.
(3) 5-Formylterthiophene (2.9 g) was dissolved in absolute ethanol (75 ml). NaBH4 (0.5 g) was added and stirred for 10 minutes. The solution became clear-yellow. Phosphorus oxychloride (2.5 ml) was added to an absolute ethanol and was dropped into aforementioned mixture and stirred under the nitrogen atmosphere overnight. Then the solution was extracted with ethyl acetate. The extract was washed with water and dried over anhydrous magnesium sulfate. The solvent was removed under reduced pressure. The residual solid was purified by column chromatography. Light yellowish crystals were obtained and the melting point thereof was 76-77°C. The yield was 85%. Spectral Data:
1H NMR (CDC13) , δ value
7 .20-6.87 ( , 7H, protons of thiophene) , 4 . 62 (s , 2H,
-CH2OC2H5)
3.55 (q, 2H, -CH2OCH2CH3) , 1.25 (t, 3H, -OCH2CH3) IR (KBr) : cm"1
3050 (aromatic CH) , 2971, 2852 (saturated CH) , 1091 (OO) Mass spectrum, m/e (relative intensity)
306 (M+, 100), 261 (M -OC2H5, 33)
Example 10
Synthesis of ethyl 5- (2 ,2'-bithienyl) -α-cγanoacrylate
5-Formyl-2 , 2 ' -bithiophene (3.9 g) , cyano-ethyl-acetate (2.4 ml), pyridine (15 ml) and piperidine (2.4 ml) were mixed together at 80-85 °C for 2 hours. After cooling, the mixture was acidified by diluted HCl and then filtered. Orange solid was thus obtained and recrystallized from ethanol to give crystalline product (5.02 g) . The melting point of the product was 131°C. The yield was 86%. Spectral Data: IR (KBr) : cm"1
2218, 1687 (-CN) 1699, 1687 (C=0) 1630, 839, 796, 729 (thiophene) Mass spectrum, m/e (relative intensity) 289 (M+)
Example 11 Synthesis of methyl 4- (2.2'-bithiophen-5-yl) -2-oxo- but-3-enoate 4-(Bithiophen-5-yl) -2-oxo-but-3-enoic acid (0.62 g) was dissolved in a mixture of methanol (25 ml) and benzene (15 ml) . A trace amount of p-toulenesulfonic acid was added and heated for 6 hours. The solution was monitored by thin layer chromatography. After the reaction was completed, the solution was extracted with ethyl acetate and the extract was washed with water and NaHC03 solution. The residual solid after evaporation was purified by column chromatography, eluted with ethyl acetate/n-hexane (1/9) . Light yellowish crystals (0.63 g) were obtained and the melting point of the product was 78 °C. The yield was 97%. Spectral Data: 1H NMR (CDC13) , δ value
7.90-7.94 (d, 1H, -CH=CH-)
6.91-7.31 (m, 6H, -CH=CH-, protons of thiophene) 3.89 (S, 3H, -C00CH3)
IR (KBr) : cm-1
1730, 1690 (C=0)
1650, 1600, 1580 (conjugative unsaturated bonding) Mass spectrum (75 ev) , m/e (relative intensity) 278(M+, 16), 265(100), 219(93)
Example 12
Synthesis of 5-α-terthienylmethylidene malonic acid
5-Formyl-α-terthiophene (1.30 g) , malonic acid (1.04 g) , pyridine (20 ml) and of piperidine (0.1 ml) were mixed together at 50-60°C for 2 hours. Water (100 ml) was added after reaction was completed. The mixture was acidified by diluted HC1 and then filtered. Red solid thus obtained was recrystallized from ethanol to give 1.43 g of the product and the melting point thereof was 202-203 °C. The yield was 84%.
Example 13
Synthesis of 5-f3-hvdroxγ-l-propynyl) -2.2 '-bithiophene Hydroxy-1-propyne (48 mg) was dissolved in benzene (1 ml). 5-Iodo-2, 2 '-bithiophene (0.1 g) was added immediately and stirred. A mixture of Cul (0.05 g) , benzyltriethylammonium chloride (0.05 g) , catalyst Pd(PPh3)4
(0.1 g) and 3 ml of NaOH solution (2.5 N) were mixed together at room temperature and stirred for 2 hours.
NH4C1 solution (4 ml) was then added. The reaction solution was extracted with ethyl acetate. The extract was washed with 10 ml of HC1 (10%) for 3 times, 50 ml of water twice and dried over anhydrous magnesium sulfate. The residual solid was purified by silica gel column chromatography, eluted with ethyl acetate/n-hexane (3/1) to yield 56 mg of the product (74%) .
Spectral Data:
XH NMR 400 MHz (CDC13) , <S value 2.3 (b, 1H, -OH), 4.5 (s, 2H, -CH2)
6.9-7.3 (m, 5H, protons of thiophene) 13C-NMR (CDC13) , δ value
51.50, 78.89, 92.19, 121.11, 123.48, 128.06, 133.4, 136.70, 139.25 IR (neat) : cm"1
3350 (OH) , 2250 (C≡C)
Preparation of 5-iodo-2.2 '-bithiophene and 5,5'-diiodo- 2.2' -biothiophene To a solution of 2 , 2 ' -biothiophene (33.2g) in ethanol (50 ml) was added iodine (20.3 g) in ethanol (200 ml). Then iodine (V) oxide (6.7 g) in water (30 ml) was added dropwisely. The reaction mixture was further stirred at room temperature for 5 hours. Ethanol was removed and the residue was dissolved in dichloromethane. The solution was washed with sodium bicarbonate aqueous solution (10%, 150 ml x 2) then water (200 ml x 2) . Dried over anhydrous magnesium sulfate and concentrated to give crude products. Distilled under vacuum ( 105-110°C/0.1 mm Hg) to give 5- iodo-2, 2 '-bithiophene (36.8 g, 63%). The residue was then separated by silica gel chromatography eluted with n-hexane to give 5, 5' -diiodo-2, 2 '-bithiophene (5.36 g, 6.4%), melting point 170°C. Spectral Data: 5-iodo-2, 2 '-biothiophene H NMR (CDCI3) , δ value
7.20 (m, protons of thiophene) Mass spectrum, m/e (relative intensity) 292 (M+, 100), 165 (M+-I, 14) 5, 5 '-diiodo-2, 2 '-biothiophene XH NMR (CDCI3) , δ value
7.05 (d) , 6.7 (d) Mass spectrum, m/e (relative intensity) 418 (M+, 100), 291 (M+-I, 9)
Example 14
Synthesis of 5- ( 2 .2 '-bithiophen-5-yl) -prop-2- yn-1-ol-acetate
5- (3-Hydroxy-l-propyne) -2, 2 '-bithiophene (0.8 g) was dissolved in acetic anhydride (0.5 ml) and pyridine (1.5 ml) at room temperature and stirred for 2 hours. The reaction solution was extracted with ethyl acetate. The extract was washed with 10 ml of HCl (10%) for 3 times, 10 ml of NaOH solution for 3 times, 50 ml of water twice and dried over anhydrous magnesium sulfate. The residual solid after evaporation was purified by silica gel column chromatography eluted with ethyl acetate/n-hexane (1/10) . Light brownish-yellow oily product (0.71 g, 73%) was obtained. Spectral Data:
XH NMR (CDC13) , δ value
2.11 (S, 3H, -CH3) , 4.90 (s, 2H, -CH2) 6.97-7.22 (m, 5H, protons of thiophene) IR (neat) : cm"1 2250 (C≡C) , 1745 (C=0) , 1225
Mass spectrum, m/e (relative intensity) 262 (M+, 100), 202 (65)
Example 15
Synthesis of ethyl-5-α-terthienylpropiolate
Ethyl propiolate (78 mg) was dissolved in benzene (3 ml) . 5-Iodo-α-terthiophene (0.2 g) was added immediately and stirred. A mixture of Cul (0.05 g) , benzyltriethylammonium chloride (0.05 g) , catalyst Pd(PPh3)4 (0.1 g) and 5 ml of NaOH solution (2.5 N) were mixed together. The temperature of the mixture was then raised to 40°C and stirred for 5 more hours. Then 5 ml of NH4C1 solution was added. The reaction solution was extracted with ethyl acetate. The extract was washed with 10 ml of HCl (10%) 3 times, 50 ml of water twice and dried over anhydrous magnesium sulfate. The residual solid after evaporation was purified by silica gel column chromatography, eluted with ethyl acetate/n-hexane (1/15) . Light brown product (78 mg, 42%) was then obtained and the melting point thereof was 93 °C. Spectral Data: 2H NMR (CDC13) , δ value
1.35 (t, 3H, -CH3) , 4.31 (q, 2H, -CH2) 6.90-7.41 (m, 5H, protons of thiophene) IR (KBr) : cm"1
2200 (C≡C) , 1705 (C=0) Mass spectrum, m/e (relative intensity) 344 (M+, 17), 248(100)
Preparation of 5-iodo-α-terthiophene α-Terthiophene (2.33 g) was dissolved in ethanol (70 ml). Iodine (1.10 g) in ethanol (25 ml) was added and then iodic acid (0.47 g) in water (1.0 ml) was added dropwisely and the temperature was kept below 31°C. The reaction mixture was further stirred for 4 hours. Precipitate from the reaction was filtered and recrystallized to give product (97.3% yield), melting point 146-148°C.
Example 16
Synthesis of 5-α-terthienylacrylic acid (NSC code # 637391) 5-Formyl-α-terthiophene (276 mg) , malonic acid (0.212 g) , pyridine (10 ml) , and piperidine (1 ml) were reacted together in water bath for 2 hours and refluxed for 30 minutes in oil bath and then cooled down to room temperature. The reaction solution was then poured into water. The mixture was acidified by diluted HCl. After standing at room temperature for 3 hours, the reddish-brown solid was filtered, washed with water and recrystallized from 95% of ethanol to give copper red needle-like crystals and the melting point thereof was 237-238 °C. The yield was 78.6%. Spectral Data:
UV: λmax: 395 nm IR (KBr) : cm"1
3200-2300 (OH) , 1672 (C=0) , 1616 (CH=CH) λH NMR (d6 -DMSO) : <S value 6.13 (1H,-CH=CH-C00H, d, J=16) , 7.70 (1H, -CH=CH-COOH, d, J=16)
7.1-7.6 (m, 7H, protons of thiophene) Mass spectrum, m/e (relative intensity) 318 (M+)
Example 17 Synthesis of methyl 4-(α-terthiophene-5-yl) -2-oxo- but-3-enoate
4-(α-Terthiophene-5-yl) -2-oxo-but-3-enoic acid (0.2 g) was dissolved in ethanol (20 ml) . A trace amount of p-toluenesulfonic acid was added and refluxed overnight. Then the solution was extracted with ethyl acetate. The extract was purified by column chromatography, eluted with ethyl acetate/n-hexane (1/9) . Dark reddish crystal product was then obtained.
Spectral Data:
XH NMR (CDCI3) , δ value
7.9-7.94 (d, 1H, -CH=CH-)
7.01-7.32 (m, 6H, -CH=CH-, protons of thiophene) 3.91 (s, 3h, -COOCH3)
Mass spectrum (75 ev) : m/e (relative intensity)
360 (M+, 53), 301 (100), 282 (23)
Preparation of 4-(α-terthiophene-5-yl) -2-oxo-but-3-enoic acid
To a solution of 5-formyl-α-terthiophene (0.5 g) in ethanol (200 ml) was added a solution of sodium pyruvate (0.3 g) in water (3 ml) at room temperature. Then 50% sodium hydroxide solution (1 ml) was added and stirred at room temperature for over night. After acidification with 10% hydrochloric acid, the resultant was extracted with ethyl acetate (200 ml x 2) . The extract was condensed under reduced pressure and the darkish solid obtained was used for methyl esterification.
Example 18 Synthesis of 5-formyl-α-tetrathiophene (NSC code # 645273) Dimethyl formamide (30 ml) was stirred and cooled in ice bath for 10 minutes. P0C13 (0.2 ml) was added into the solution at O'C and stirred for 1 hour. Dimethyl formamide (20 ml) solution of α-tetrathiophene (0.5 g) was dropped in slowly. The mixture was stirred for 1 hour at O'C, then the temperature was raised to room temperature, and further stirred for 8 hours at 70 'C. The cold reaction solution was poured into NaOH ice water solution, and extracted with dichloromethane. The extract was washed with 50 ml of water for 3 times, dried over anhydrous magnesium sulfate and concentrated. The residual solid was further purified by silica gel column chromatography, eluted with
n-hexane/tetrahydrofuran (1/1). Dark yellow solid (0.22 g, 41%) product was obtained after recrystallization from n-hexane and tetrahydrofuran. The melting point of the product was 215 'C. Spectral Data: H NMR (CDC13) , δ value
7.00-7.66 (m, 9H, protons of thiophene)
9.84 (s,- 1H, -CHO) IR (KBr) : cm"1 1665 (C=0)
Mass spectrum, m/e (relative intensity)
358 (M+, 100)
Preparation of α-tetrathiophene 5-Iodo-2, 2 '-bithiophene (10 g, 34.2 mmole) and copper powder (2.8 g, 44.0 mmole) was mixed together. Dimethyl formamide (20 ml) was added and heated to reflux for 6 hours. The reaction mixture was extracted with tetrahydrofuran and decanted to separate the unreacted copper powder. The solvent was removed and the residue was separated by silica gel chromatography eluted first with n-hexane to recover starting material and then with n-hexane/tetrahydrofuran (2:1) to give product. Light yellowish crystals were obtained after recrystallization (34.8% yield), melting point 208°C.
Example 19
Synthesis of 5-hγdroxymethyl-α-tetrathiophene (NSC code # 645274) 5-Formyl-α-tetrathiophene (180 mg) was dissolved in dimethyl formamide (10 ml) solution. NaBH4 (0.1 g)was then added. The mixture was stirred for 2 hours at room temperature. Then the solution was extracted with dichloromethane and washed with 10 ml of water twice and dried over anhydrous magnesium sulfate. After evaporation
the residual solid was purified by silica gel column chromatography and further recrystallized from THF and n-hexane. Light orange solid (150 mg, 82.4%) was obtained and the melting point of the product was 216°C. Spectral Data: IR (KBr) : cm"1
3300 (OH) Mass spectrum, m/e (relative intensity)
360 (M+, 100) 344 (21)
Example 20
Synthesis of 5- (4-hvdroxy-l-butvnyl) -2.2 '-bithiophene
(1) Hydroxy-1-butyne (0.23 g) was dissolved in benzene (1 ml). 5-Iodo-2, 2 '-bithiophene (0.3 g) was added immediately and stirred. Cul (0.05 g) , benzyltriethylammonium chloride (0.05 g) , Pd(PPh3)4 (0.1 g) and NaOH solution (2.5 N) (4 ml) were mixed together at room temperature and stirred for 2 hours. NH4C1 solution (5 ml) was then added. The reaction solution was extracted with ethyl acetate. The extract was washed with 10 ml of HCl (10%) for 3 times, 50 ml of water twice and dried over anhydrous magnesium sulfate. The residual solid after evaporation was purified by silica gel column chromatography, eluted with ethyl acetate/n-hexane (1/3). Light yellowish product (0.21 g, 75%) was obtained and the melting point thereof was 67°C.
(2) In a brown three-necked round bottom flask equipped with condenser, thermometer and nitrogen inlet was added 5-iodo-2, 2 '-bithiophene (17.07 g) and pyridine (100 ml). 3-Butyn-l-ol cuperous salt was quickly added and refluxed under nitrogen atmosphere for 3.5 hours. Pyridine was then distilled and the reaction mixture was extracted with dichloromethane (100 ml x 2) . The extract was washed with water (150 ml x 2) , 10% sodium bicarbonate aqueous solution (100 ml x 2) and again water (150 ml x 2) to remove water
soluble compounds. The organic layer was dried over anhydrous magnesium sulfate, concentrated and separated by silica gel chromatography eluted with n-hexane to recover starting material (3.56 g) and then with n-hexane/ethyl acetate (6:1) to give light yellowish crystalline product (8.49 g, 62%) . Spectral Data: 2H NMR (CDC13) , δ value
7.20-6.75 ( , 5H, protons of thiophene), 3.7 (t, 2H, CH2OH) ,
2.7 (t, 2H, CH2CH2OH) IR: cm"1
3300 (br, 0-H) , 1032 (OO) Mass spectrum: m/e (relative intensity) 234 (M+, 17) , 203 (M+-CH20H, 10) , 84 (100)
Example 21
Synthesis of 5- (4-acetoxy-l-butvnyl) -2.2 '-bithiophene 4- (Hydroxy-1-butynyl) -2, 2 '-bithiophene (1.23 g) was dissolved in pyridine (6 ml) . Acetic anhydride (1 ml) was added at room temperature, stirred for few minutes and further kept overnight. Water (20 ml) was added oily product was then extracted with 30 ml of ethyl acetate. The extract was washed with 10 ml of HCl (IN) for 3 times, 10 ml of water once and 10 ml of diluted KHC03 solution once. Ethyl acetate was then removed under reduced pressure. The residual solid was purified by silica gel column chromatography, eluted with ethyl acetate/n-hexane (1/19). Light yellowish oily product (1.3 g) was obtained after removal of the solvent. Spectral Data: NMR: δ value
7.3-6.8 (m, 5H, protons of thiophene), 4.16 (t, 2H, -CH2-CH2-0-) 2.7 (t, 2H, -CH2-CH2-0-) , 2.0 (t, 3H, -OCOCH3)
3035 (aromatic C-H) 2960, 2900 (adipose C-H) 1737, 1232, 1038 (ester) Mass spectrum, m/e (relative intensity) 276 (M+, 46) , 216 (M+-AcOH, 100)
Example 22
Synthesis of 5- (4-isovaleryloxy-l-butynyl) -2.2'- bithiophene
5-(4-Hydroxy-l-butynyl) -2 ,2 '-bithiophene (1 g) was dissolved in pyridine (10 ml) . Isovaleroyl chloride (1 ml) was added at room temperature, stirred for few minutes and kept overnight. The reaction mixture was treated as in example 21. Light yellowish oily product (1.06 g) was then obtained. Spectral Data: λK NMR: δ value
6.95-7.1 (m, 5H, protons of thiophene), 4.2 (t, 2H, J=7Hz, -CH2-CH2-0-)
2.72 (t, 2H, J=7Hz, -CH2-CH2-0-) , 2.18 (br.s. 2H, -0-C0-CH2-)
2.2-1.9 (m, 1H, -CH2-CH(CH3)2) , 0.96 (1, 6H, J=6Hz , CH(CH3)2) IR: cm-1
3100, 3070 (aromatic C-H), 2960-2870 (aliphatic C-H) 1730, 1250, 1150 (ester) 1460, 1380, 1360 (-CH(CH3)2) 834, 795, 692 (2 , 2 ' -bithiophene) Mass spectrum, m/e (relative intensity)
318 (M+, 15), 216 (M+- (CH3) 2CHCH2COOH, 100)
Example 23 Synthesis of 5-(4-benzoxy-l-butynyl) -2.2'- bithiophene 5-(4-Hydroxy-l-butynyl)-2,2'-bithiophene (0.8 g) was
dissolved in pyridine (8 ml) . Benzoyl chloride (1 ml) was added at room temperature, stirred for few minutes and kept overnight. The reaction mixture was treated as in example 21. Light yellowish crystals were then obtained and the melting point thereof was 61°C. Spectral Data: XH NMR: δ value
6.86-8.28 (m, 10H, aromatic H)
4.42 (t, 2H, -CH2-CH2-0-) , 2.85 (t, 2H, -CH2-CH2-0-) IR: cm"1
3090, 3040 (aromatic C-H) 1695, 1268, 1109 (aromatic ester) Mass spectrum, m/e (relative intensity) 388 (M+, 16) , 216 (M+-C6H5COOH, 100)
Example 24 Synthesis of 5-(4-palmityloxy-l-butynyl) -2.2'- bithiophene
5- (4-Hydroxy-l-butynyl) -2, 2 '-bithiophene (0.6 g) was dissolved in pyridine (10 ml) . Palmitoyl chloride (1 ml) was added at room temperature, stirred for few minutes and kept overnight. The reaction mixture was treated as in example 21, and 1.2 g of light yellowish crystals were then obtained and the melting point thereof was 68-69°C. Spectral Data: λE NMR: <S value
7.26-6.84 (m, 5H, protons of thiophene) 4.25 (t, 2H, -CH2-CH2-0-) , 2.67 (t, 2H, -CH2-CH2-0-) 2.28 (t, 2H, -OCOCH2C14H29) , 1.22 broad (m, 29H, -OCOCH2C14H29) IR: cm-1
3030 (aromatic C-H), 2950, 2840 (aliphatic C-H) 1730, 1170 (ester) Mass spectrum, m/e (relative intensity) 472 (M+, 25), 216 (M+-C15H31COOH, 100)
Example 25
Synthesis of 5- (3-hydroxy-4-pyranyloxy) -l-butynyl-2.2 '- bithiophene
4-(Tetrahydropyranyloxy) -3-hydroxy-butyne (6.7 g) was dissolved in benzene (20 ml). 5-Iodo-2.2 '-bithiophene
(5.75 g) was added immediately and stirred. A mixture of Cul (0.15 g) and benzyltriethylammonium chloride (0.14 g, 0.63 mmole was added. Pd(PPh3)4 (0.46 g, 0.398 mmole) was then added. NaOH solution (30 ml, 2.5 N) was added slowly into the mixture at room temperature in water bath for 2 hours. NH4C1 solution (10 ml) was added. The reaction solution was extracted with ethyl acetate. The extract was washed with 10 ml of HCl (10%) for 3 times, 50 ml of water for 3 times and dried over anhydrous magnesium sulfate. The residual solid after evaporation was purified by silica gel column chromatography, eluted with ethyl acetate/n-hexane (1/3) . Reddish oily product (6.25 g, 95%) was then obtained. Spectral Data: λ NMR (CDC13) , δ value
1.4-1.9 (m, 6H, 3CH3) , 3.3-4.0 (m, 4H, 2CH2) 4.5-4.7 (m, 1H, CH) , 6.9-7.2 (m, 5H, protons of thiophene) IR (neat) : cm"1 3400 (OH), 2950 (C-H), 2250 (C≡C)
Mass spectrum, m/e (relative intensity)
334(80, M+) , 304(41), 234(49), 190(51), 86(100)
Preparation of 3-hvdroxy-4-(tetrahydro-2- pyranyloxy) -butyne
Acetylene gas was bubbled into tetrahydrofuran (30 ml) for 30 minutes. Ethyl magnesium bromide (25 ml) was added.
2-(Tetrahydro-2-pyranyloxy) -acetaldehyde (5.0 g, 0.035 mole) in tetrahydrofuran (25 ml) was then added. The
reaction mixture was warmed to room temperature and stirred overnight. Saturated ammonium chloride aqueous solution (30 ml) was added to quench the unreacted acetylide and extracted with ethyl acetate. The extract was dried over anhydrous magnesium sulfate, concentrated and separated by silica gel chromatography eluted with n-hexane/ethyl acetate (5:2) to give colorless oil (4.5 g, 76%). Spectral Data: λE NMR (CDC13) , δ value 4.6-4.4 (m, 2H, 2CH) , 3.8-3.6 (m, 2H, CH2) , 3.5-3.4 (m,
2H, CH ) ,
2.4 (s, 1H, C≡CH) , 1.9-1.4 (m, 4H, 2CH2) IR (neat) : cm"1
3600-3000 (O-H) , 2150 (C≡C) Mass spectrum: m/e (relative intensity)
169 (M+-l) , 115 (13), 97 (19), 85 (100), 56 (48)
Preparation of 2-(tetrahydro-2-pyranyloxy) - acetaldehyde 2-(Tetrahydro-2-pyranyloxy) -propene (20 g, 0.14 mole) was dissolved in dichloro-methane (250 ml) . Ozone was bubbled into the solution at -78°C for about 3 hours until the solution turned blue. Warmed to room temperature and zinc powder (20 g) was added. Acetic acid (20 ml) and water (3 ml) were added slowly with cooling in ice bath. The reaction mixture was further stirred for 2 hours at room temperature and then extracted with dichloromethane. The extract was washed with sodium bicarbonate aqueous solution (10 ml x 2) , dried over anhydrous magnesium sulfate, concentrated. The crude product was distilled under vacuum (62-64°C/2 mmHg) gave colorless oil (13.72 g, 68%). 2- (Tetra-hydro-2-pyranyloxy) -propene was directly prepared from allyl alcohol and dihydropyran in the presence of a small amount of p-toluenesulfonic acid. Spectral Data:
NMR (CDC13) , δ value
9.7 (s, 1H, CHO), 4.6 (t, 1H, 0-CH-O) , 1.9-1.3 (m, 6H,
CH2) 13C NMR (CDC13) , δ value
200.78, 100.89, 74.29, 63.89, 31.39, 26.35, 20.35
(neat) : cm-1
2950 (C-H) , 1735 (C=0)
Example 26 Synthesis of 5-(3-acetoxy-4-tetrahvdropyranyloχy)-l- butγnyl-2 , 2 ' -bithiophene
3-Acetoxy-4-tetrahydropyranyloxy-l-butyne (4.73) was dissolved in benzene (15 ml). 5-Iodo-2 , 2 '-bithiophene (5.15 g) was added immediately and stirred. A mixture of Cul (0.13 g) , benzyltriethylammonium chloride (0.12 g) and catalyst Pd(PPh3)4 (0.4 g) was then added. NaOH solution (20 ml, 2.5 N) was added slowly into the mixture at room temperature for 2 hours. Saturated NH4C1 solution (8 ml) was added. The reaction mixture was extracted with ethyl acetate. The extract was washed with 10 ml of HCl (10%) twice, 50 ml of water twice and dried over anhydrous magnesium sulfate. The residual solid after evaporation was purified by silica gel column chromatography, eluted with ethyl acetate/n-hexane (1/3) . Light orange product (4.1 g, 67%) was obtained.
Spectral Data:
2H NMR (CDC13) , δ value
1.4-1.9 (m, 6H, 3CH2) , 2.1 (s, 3H, CH3) 3.7-4.0 (m, 4H, 2CH2) , 4.7-4.8 (s, 1H, OCHO)
5.7-5.9 ( , 1H, CH) , 7.0-7.3 (m, 5H, protons of thiophene) IR (neat) : cm"1
2950 (C-H) , 2225 (C=C) , 1750 (C=0) Mass spectrum, m/e (relative intensity)
376 (M+ , 69 ) , 333 ( 21 ) , 275 ( 30 ) , 234 ( 100 )
Preparation of 3-acetoxγ-4- ttetrahvdro-2- pyranyloxy) -butyne 3-Hydroxy-4-(tetrahydro-2-pyranyloxy) -butyne (8.0 g, 0.047 mole) was mixed with acetic anhydride (10 g, 0.098 mole) and pyridine (8 g, 0.098 mole). The solution was stirred at room temperature for 1 hour and then extracted with ethyl acetate. The extract was sequentially washed with 10% hydrochloric acid (10 ml x 5) , saturated sodium bicarbonate aqueous solution (10 ml x 5) and water (50 ml x 3) . The extract was dried over anhydrous magnesium sulfate, concentrated and separated by silica gel chromatography, eluted with n-hexane/ethyl acetate (5:1) to give colorless oil (9.0 g, 90%).
Example 27
Synthesis of 5- (3-acetoxy-4-hvdroxy-l-butγnyl) -2.2'- bithiophene (NSC code # 645277)
5- (3-Acetoxy-4-tetrahydropyranyloxy-l-butynyl) -2,2'- bithiophene (2.8 g) was dissolved in methanol (40 ml). H2S04 solution (3 ml, 2N) was added slowly in ice bath and stirred at room temperature for 2 hours. The reaction solution was extracted with ethyl acetate. The extract was thus washed with 10 ml of NaHC03 three time, 50 ml of water twice and dried over anhydrous magnesium sulfate. After removal of solvent residual solid was purified by silica gel column chromatography, eluted with ethyl acetate/n-hexane (1/3) . Light brown product (1.83 g, 84%) was obtained. Spectral Data: λH NMR (CDC13) , <S value
2.15 (s, 3H, -CH3) , 3.90 (d, 2H, -CH2) 5.71 (t, 1H, CH) , 7.0-7.3 (m, 5H, protons of thiophene)
IR (neat) : cm"1
3450 (OH) , 2250 (C≡C) , 1730 (C=0)
Example 28 Synthesis of 5- (3.4-diacetoxy-l-butvnyl) -2.2'- bithiophene 5- (3-Acetoxy-4-hydroxy) -butynyl-2, 2 '-bithiophene (1.83 g) was dissolved in pyridine (1.5 g) and acetic anhydride (1.27 g) at room temperature for 2 hours. The reaction solution was extracted with ethyl acetate. The extract was washed with 10 ml of HCl (10%) for 3 times, 10 ml of KHC03 solution for three times and 50 ml of water twice. The solution was then dried over anhydrous magnesium sulfate. After removal of solvent residual solid was purified by silica gel column chromatography, eluted with ethyl acetate/n-hexane (1/5) . Greenish yellow oily product (1.91 g, 91%) was then obtained. Spectral Data: λE NMR (CDC13) , <S value
2.07 (s, 3H, -CH3) , 2.12 (s, 3H, -CH3) 4.25-4.45 (m, 2H, CH2) , 5.80-5.87 (m, 1H, CH) 7.0-7.3 (m, 5H, protons of thiophene) IR (neat) : cm"1
2250 (C=C) , 1755 (C=0) , 1735 (C=0) Mass spectrum, m/e (relative intensity) 334 (M+, 75), 274(100), 232(55)
Example 29
Synthesis of 5.5'-dihvdroχymethyl-2-2 '-bithiophene (NSC code # 647452)
(1) 5-Hydroxymethyl-5' -formy1-2, 2 '-bithiophene (0.2 g) was dissolved in ethanol (50 ml). NaBH4 (0.1 g) was added at room temperature and stirred for 1 hour. The reaction was monitored by thin layer chromatography. After the reaction was completed, H20 (50 ml) was added and the
ethanol was removed under reduced pressure. Light yellowish solid product was obtained. The yield was almost quantitative and the melting point of the product was 158-160°C. Spectral Data: λE NMR (d6-acetone)
7.03-6.87 (m, 4H, protons of thiophene)
4.73 (S,.4H, -CH20H) IR (KBr) : cm"1 3500-3300 (OH) , 3050 (aromatic CH)
2909, 2850 (aliphatic CH) Mass spectrum, m/e (relative intensity)
226 (M+, 100), 209 (M+-0H, 73)
(2) 5-Hydroxymethyl-5'-formyl-2, 2 '-bithiophene (0.6 g) was dissolved in tetra-hydrofuran (30 ml), NaBH4 (0.16 g) was added, and the solution was stirred for 2 hours at room temperature. The solvent was removed under reduced pressure. White solid obtained was washed with water and dried under reduced pressure. The yield was quantitative. The melting point of the product was 155-156°C.
(3) 5-Hydroxymethyl-5'-formyl-2, 2 '-bithiophene (0.5 g) was reduced in ethanol (75 ml) with NaBH4 (0.3 g) . The mixture was stirred for 3 hours at room temperature. The solution was concentrated and n-hexane was added to obtain white product. The product was washed with water, dried under reduced pressure and the yield was quantitative. The melting point of the product was 155-156°C.
(4) 2-Hydroxymethyl-5-iodothiophene was refluxed with Cu powder in dimethyl formamide. The Ullmann condensation also produced 5 , 5 ' -dihydroxy-methyl-2 , 2 ' - bithiophene in low yield.
(5) The Ullmann condensation of 2-acetoxymethyl-5- iodothiophene gave 5,5' -diacetoxymethyl-2 , 2 ' -bithiophene . The 5,5' -dihydroxymethyl-2 , 2 ' -bithiophene was obtained by alkaline hydrolysis of diacetoxy compound and purified by
column chromatography. The yield was about 20%.
Example 30
Synthesis of 5.5' -diacetoxymethyl-2-2 '-bithiophene 5 , 5 ' -Dihydroxymethy1-2 , 2 '-bithiophene (0.23 g) , pyridine (1.2 ml) and acetic anhydride (0.3 ml) were mixed, stirred and kept overnight. Then the mixture was extracted with ethylacetate. The pyridine and acetic acid were removed by washing with weak base, weak acid and water, respectively. Silica gel powder was added into the ethyl acetate solution and the solvent was removed under reduced pressure. Coated silica gel powder was added to the silica gel column and chromatographed. The eluant was ethyl acetate/n-hexane (7/3) . The white platelet crystal thus obtained was further recrystallized with ethyl acetate/n-hexane mixture. The melting point of the product was 60°C. Spectral Data: IR: cm"1
1725 (C=0) Mass spectrum, m/e (relative intensity) 310 (M+, 37) 251 (M+-CH3C02, 100) 192 (M+-2CH3C02, 34)
Example 31
Synthesis of S-hydroxymethyl-S'-formyl-Σ-Σ'-bithiophene (NSC code # 647073)
Phosphorus oxychloride ("P0C13") (1 ml) was added into dimethyl formamide (20 ml) slowly under nitrogen gas atmosphere in ice bath and stirred for 1 hour. The dimethyl formamide solution (5 ml) of 5-hydroxymethyl- 2 , 2 '-bithiophene (0.5 g) was dropped in slowly. The mixture was stirred for half an hour at room temperature, then the temperature was raised to 50°C and was further stirred for 3 hours. The reaction solution was poured into
potassium carbonate ice water solution. Then the solution was extracted with 100 ml of ethyl acetate. The extract was washed with water and dried over anhydrous magnesium sulfate. The solvent was removed under reduced pressure, and the residual solid was purified by column chromatography, eluted with ethyl acetate/n-hexane (3/7) . Light yellowish product was recrystallized from ethyl acetate/n-hexane mixture. The melting point of the product was 123-124°C. The yield was 85%. Spectral Data: λE NMR 400 MHz (CDC13) , <S value
9.91 (s, 1H, -CHO), 7.73-7.02 (m, 4H, protons of thiophene)
4.91-4.90 (d, 2H, -CH20H) IR (KBr) : cm"1
3300 (OH) , 1640 (C=0) Mass spectrum, m/e (relative intensity)
224 (M+, 100), 207 (M+ -OH, 57), 195 (M+ -OH CHO, 22)
Preparation of 5-hydroxymethyl-2.2 '-bithiophene
To a solution of 5-formy1-2, 2 '-bithiophene (20 g) in methanol (50 ml) was added sodium borohydride. The reaction mixture was stirred at room temperature and monitored with thin layer chromatography until the reaction completed. After removal of methanol, water was added to dissolve inorganic salts and extracted with dichloromethane. The extract was washed with brine, dried over anhydrous magnesium sulfate, concentrated to give product (20.1 g, 99%), melting point 52-53°C. Spectral Data: E NMR (DMSO-D6) , δ value
7.4-6.6 (m, 5H) , 5.51 (t, 2H) , 4.5 (d, 2H)
UuVvmax :'
320-300nm IR: cm
3250 (O-H) Mass spectrum: m/e 196 (M+)
Example 32
Synthesis of 5-acetoxymethyl-5'-formγl-2-2' -bithiophene
(NSC code # 647453) 5-Hydroxymethyl-5'-formyl-2, 2 '-bithiophene (0.2 g) and pyridine (1 ml) were mixed together. Acetic anhydride (1 ml) was added slowly into the mixture with stirring. Ethyl acetate (200 ml) and water (50 ml) were added 2 hours later. The ethyl acetate layer was washed with weak base, weak acid and water. The product was concentrated and purified by column chromatography, eluted with ethyl acetate/n-hexane (1/9) . Light yellowish crystals were obtained. The melting point of the crystal was 89-91°C.
The yield was 95%.
Spectral Data:
1H NMR 400 MHz (CDC13) , δ value 9.83 (s, 1H, -CHO), 7.64-7.01 (m, 4H, protons of thiophene) 5.20 (s, 2H, -CH2OAc) , 2.08 (s, 3H, -COCH3)
IR (KBr) : cm"1
1740, 1660 (C=0)
Example 33
Synthesis of 5-hvdroxymethyl-5"-formy1-α-terthiophene (NSC code # 647455) P0C13 (1 ml) was added to dimethyl formamide (30 ml) slowly under nitrogen stream in ice bath. The solution was stirred for 0.5 hour and then dimethyl formamide solution (20 ml) of 5-hydroxymethyl-α-terthiophene (0.3 g) was dropped in slowly. The mixture was stirred for an hour at room temperature and then the temperature was raised to 60°C and stirred for 2 more hours. The reaction solution
was poured into ice aqueous potassium carbonate solution. The solution was extracted with 300 ml of ethyl acetate and the extract was washed with water. The solvent was removed under reduced pressure and the residual solid was purified by column chromatography, eluted with ethyl acetate/n-hexane (3/7) . Orange crystals were obtained and the melting point of the product was 176-177 °C. The yield was 80%. Spectral Data: λE NMR (CDC13) , δ value
9.86 (s, 1H, -CHO), 7.65-6.91 (m, 6H, protons of thiophene)
4.80 (s, 2H, -CH2OH) IR (KBr) : cm"1 3400 (OH) , 1660 (C=0)
Mass spectrum, m/e (relative intensity)
306 (M+, 100), 289 (M+,-OH, 56)
Preparation of 5-hvdroxγmethyl-α-terthiophene To a solution of 5-formyl-α-bithiophene (0.5 g) in tetrahydrofuran (20 ml) was added sodium borohydride (0.034 g) . The reaction mixture was stirred at room temperature for 2 hours and monitored with thin layer chromatography until the reaction completed. Water (50 ml) was added slowly and extracted with chloroform. The extract was dried over anhydrous magnesium sulfate, concentrated to give yellowish powder, melting point 151-152 °C, yield 97%. Spectral Data: E NMR (DMS0-d6) , δ value 7.51 (d, 1H, J=4Hz) , 7.31 (dd, 1H, Jχ=l, 4Hz) , 7.24 (d, 1H, J=4HZ) , 7.20 (d, 1H, J=4Hz) , 7.15 (d, 1H, J=4Hz) , 7.09 (dd, 1H, J=3.5, 4Hz) , 6.91 (d, 1H, J=4Hz) , 5.52 (d, 1H, J=6HZ) , 4.60 (d, 2H, J=6Hz)
UVmax: λmax: 355nm
IR (KBr) : cm"1
3300 (O-H) , 3061 (=OH) , 2950 (-C-H) , 1060 (OO) Mass spectrum: m/e 278 (M+)
Example 34 Synthesis of 5, 5"-dihγdroxymethγl-α-terthiophene (NSC code # 646270) 5,5"-Diformyl-α-terthiophene (1 g) was added into tetrahydrofuran (150 ml) . The temperature was raised to 50°C until the solid was completely dissolved, then NaBH4 (0.25 g) was added and stirred for 3 hours at 50°C. The solvent was removed under reduced pressure. Ethyl acetate and water were added to dissolve the residual solid. The ethyl acetate layer was washed with water and dried over anhydrous magnesium sulfate. The ethyl acetate layer was filtered and concentrated to obtain light yellowish crystals (0.95 g) and the melting point of the product was 182-183°C. Spectral Data:
1H NMR 400 MHz (CDC13) , <S value
7.04-6.89 (m, 6H, protons of thiophene) 4.79 (d, 4H, CH2OH) , 1.51 (br. s. , OH) Mass spectrum, m/e (relative intensity) 308 (M+, 58), 306 (M+-2H, 100)
Example 35
Synthesis of 5-hγdroxymethyl-5"-f1-hγdroxγpropyl) - α-terthiophene (l) P0C13 (0.5 ml) was added to dimethyl formamide (30 ml) slowly under nitrogen stream in ice bath condition. The solution was stirred for 1 hour and dimethyl formamide solution (200 ml) of 5-hydroxymethyl-α-terthiophene (0.8 g) was dropped in slowly. Then heated to 70°C with oil bath for 3 hours. The reaction solution was thus placed into 50
ml of aqueous K2C03 solution at 0°C. The solution was extracted with 500 ml of ethyl acetate. The residual solid was purified by column chromatography, eluted with ethyl acetate/n-hexane (3/7) . After removal of solvent, the residue was dissolved in 50 ml of tetrahydrofuran under nitrogen stream and dropped in 1 ml of Ethyl Grignard reagent and stirred at room temperature for 3 hours. The solution was monitored by thin layer chromatography. After the reaction was completed, then the solution was extracted with 300 ml of ethyl acetate and 50 ml of water. After removal of solvent, the residual solid was purified by column chromatography, eluted with ethyl acetate/n-hexane (3/7) . Orange powder was thus obtained and the melting point of the product was 131°C. (2) 5-Hydroxymethyl-5"-formyl-α-terthiophene (0.5 g) was dissolved into anhydrous tetrahydrofuran (50 ml) . A slightly excessive amount of ethyl magnesium bromide (2.0 M) was added to the solution under nitrogen atmosphere. The solution was stirred for 3 hours at room temperature. Aqueous ammonium chloride solution was added to hydrolyze the above reaction solution to obtain the crude product. The crude product was collected and purified by column chromatography, eluted with ethyl acetate/n-hexane (3/7) . The eluate was concentrated to obtain orange powder (0.3 g) . The melting point was 131-132°C. Spectral Data: λE NMR (CDC13) , <S value
7.03-6.85 (m, 6H, protons of thiophene) 4.79-4.78 (m, 3H, -CH2OH and -CHC2H5) 1.91-1.77 (m, 2H, -CH2CH3) , 0.99-0.95 (t, 3H, -CH3) IR (KBr) : cm"1
3400 (OH) , 2900 (saturated CH)
Example 36 Synthesis of 5-succinoylmethγl-2.2 '-bithiophene
5-Hydroxymethyl-2 , 2 '-bithiophene (2.5 g) , pyridine (20 ml) and succinic anhydride (1.2 g) were mixed together and stirred at 40°C. Thin layer chromatography was applied to monitor the reaction. After the reaction was completed, ethyl acetate and diluted hydrochloric acid were added.
The reaction solution was concentrated and then mixed with n-hexane for crystallization. White crystals (2.43 g) were then obtained and melting point thereof was 112 °C. Spectral Data: λE NMR (CDC13) : δ value
7.20-6.90 (m, 5H, protons of thiophene), 5.23 (s, 2H, -CH20-)
2.69-2.61 (m, 4H, -COCH2CH2CO-) , 2.40 (br, OH) IR (KBr) : cm"1 3200-2500 (OH)
1720, 1690 (C=0)
Example 37
Synthesis of 5.5' -disuccinoylmethyl-2.2 '-bithiophene 5, 5' -Dihydroxymethy1-2, 2 '-bithiophene (0.5 g) , pyridine (10 ml) and succinic anhydride (2 g) were mixed together. The mixture was stirred at 40°C. Thin layer chromatography was applied to monitor the reaction. After the reaction was completed, ethyl acetate was added to extract the product. The ethyl acetate layer was washed with diluted hydrochloric acid and water in order to remove pyridine completely. The product was filtered through silica gel and recrystallized from ethyl acetate/n-hexane. White crystals (0.45 g) were obtained. The melting point of the crystal was 137 °C. Spectral Data: λE NMR (CDC13) , δ value
7.00-6.90 (m, 4H, protons of thiophene), 5.28-5.23 (m, 4H, -CH20-) 4.78-4.75 (m, 4H, -CH20-) , 2.69-2.64 (m, 8H,
-CO-CH2CH2-CO-) IR (KBr) : cm"1 3600-2500 (OH) 1718, 1688 (C=0)
Example 38
Synthesis of 5-succinoγlmethγl-5'-formyl-2.2 '-bithiophene
5-Hydroxymethyl-5' -formy1-2, 2 '-bithiophene (0.63 g) , pyridine (10 ml) and succinyl anhydride (0.12 g) were mixed together. The mixture was stirred at 40°C. Thin layer chromatography was applied to monitor the reaction. After the reaction was completed, diluted hydrochloric acid and ethyl acetate were added. The ethyl acetate solution was washed with water to remove pyridine completely. Then the ethyl acetate layer was dehydrated with anhydrous magnesium sulfate and filtered through silica gel layer. After removal of the solvent, the product was recrystallized from ethyl acetate/n-hexane to give a light yellowish crystals (0.6 g) . The melting point was 127°C. Spectral Data: E NMR (CDC13) , δ value
9.84 (s, 1H, -CHO), 7.65-7.02 (m, 4H, protons of thiophene)
5.25 (s, 2H, -CH20-) , 2.72-2.64 (m, 4H, -COCH2CH2CO- ) 2.40 (br, OH) IR (KBr) : cm"1 3200-2500 (OH) 1730, 1705, 1650 (C=0)
Example 39
Synthesis of 5-formyl-2.2 ' : 5' .3"-terthiophene (NSC code # 660643)
In a two-necked round bottomed flask was added 5-dimethoxymethyl-5' -tributyl-stannyl-2 , 2 '-bithiophene (5.6 g) , bis (triphenylphosphine) palladium (II) chloride (0.32
g) , 3-bromo-thiophene (1.5 g) (Aldrich Chem. Co., Milwaukee, WI) and tetrahydrofuran (20 ml) . The reaction mixture was refluxed for 16 hours. To the reaction mixture was then added hydrochloric acid (I N, 3 ml) and was further refluxed for 3 hours. Saturated sodium bicarbonate aqueous solution was added to neutrality and extracted with ethyl acetate. The extract was washed with brine, dried over anhydrous magnesium sulfate and concentrated. The residue was separated by silica gel chromatography, eluted with n-hexane/ethyl acetate (9:1 → 1:1 gradient) to give brownish solid product (0.7 g, 40%), melting point 155-157°C. Spectral Data: λE NMR (CDC13) , δ value 9.86 (s, 1H) , 7.67 (d, 1H, J=3.8Hz), 7.44-7.23 (m, 5H) , 7.15 (d, 1H, J=3.8Hz) IR (CH2C12) : cm"1
1695 (C=0) Mass spectrum, m/e (relative intensity) 276 (M+, 100), 270 (12), 247 (8), 203 (24), 127 (6)
Preparation of 5-dimethoχymethyl-5'-tributylstannyl- 2.2' -bithiophene
To a solution of 5-dimethoxymethyl-2 , 2 '-bithiophene (1.0 g) in tetrahydrofuran (20 ml) with ice bath cooling was added n-butyllithium (1.6 M in hexane, 3.0 ml). The ice bath was removed and the reaction mixture was stirred at room temperature for 1 hour. Then cooled with ice bath again and tributyltin chloride (1.14 ml) was added. The reaction mixture was further stirred at room temperature for 4 hours. Solvent was removed and the residue was quickly filtered through aluminum oxide eluted with n-hexane to give desired product (1.6 g) . Spectral Data: NMR (CDC13) , δ value
7.28-7 .26 (m, 1H) , 7 . 06-7. 04 (m, 2H) , 6.97-6.94 (m,
1H) , 5 . 61 (s , 1H)
3 . 38 (s , 6H) , 1. 62-0. 87 (m, 27H)
Preparation of 5-dimethoxymethγl-2.2 '-bithiophene
Trimethyl orthoformate (7.5 ml) and montmorillonite K-10 (5.0 g) (Aldrich Chem. Co., Milwaukee, WI) were mixed and stirred at room temperature for 10 minutes. A solution of 5-formy1-2, 2 '-bithiophene (5.0 g) (Aldrich Chem. Co., Milwaukee, WI) in n-hexane (10 ml) was added and was stirred at room temperature. The reaction was monitored with thin layer chromatography until the reaction was completed. Montmorillonite K-10 was filtered. The filtrate was added to a saturated sodium bicarbonate aqueous solution and extracted with ethyl acetate (15 ml x 3) . The extract was washed with brine, dried over anhydrous magnesium sulfate and concentrated to give light yellowish oily product (6.4 g) . Spectral Data: λE NMR (CDC13) , <S value
7.19-7.13 (m, 2H) , 7.05 (d, 1H, J=4.0Hz), 7.00-6.94 ( ,
2H),
5.59 (d, 1H, J=0.5Hz), 3.37 (S, 6H)
Example 40
Synthesis of 5-hydroxymethyl-2.2 ' : 5 ' .3"-terthiophene (NSC code # 660644)
To a solution of 5-formyl-2, 2' :5' , 3"-terthiophene (0.5 g) in methanol (15 ml) was added excess amount of sodium borohydride. The reaction mixture was stirred at room temperature for 40 minutes. Methanol was removed and water was added. The solution was extracted with ethyl acetate, washed with brine, dried over anhydrous magnesium sulfate and concentrated to give brownish solid product (0.5 g) , melting point 158-160°C.
Spectral Data:
XE NMR (CDCI3) , δ value
7.40-7.27 (m, 3H) , 7.11-7.03 (m, 2H) , 6.92 (d, 1H,
J=3.49Hz), 4.81 (s, 2H) , 1.62 (brs, OH) IR (CHCI3) : cm"1
3650 (O-H) Mass spectrum, m/e (relative intensity)
278 (M+, 100), 261 (55), 245 (9), 216 (8), 203 (15), 127 (5)
Example 41
Synthesis of 4-formyl-5-hγdroxymethyl-2.2' : 5' .2"- terthiophene (NSC code # 663562)
In a two-necked round bottomed flask was added 5-tributylstannyl-2, 2 '-bithiophene (2.04 g) , bis (triphenylphosphine) palladium (II) chloride (0.19 g) , 3-formyl-2-hydroxymethyl-5-iodo-thiophene (1.0 g) and tetrahydrofuran (20 ml) . The reaction mixture was refluxed for 16 hours. Extracted with ethyl acetate, washed with brine, dried over anhydrous magnesium sulfate and concentrated. The residue was separated by silica gel chromatography, eluted with n-hexane/ethyl acetate (9:1 → 1:1 gradient) to give brownish solid product (0.43 g, 38%), melting point 108-ll0°C. Spectral Data: λE NMR (CDCI3) , δ value
10.01 (s, 1H) , 7.56 (s, 1H) , 7.45 (dd, 1H, J=1.0, 5.2Hz),
7.32 (dd, 1H, J=1.06, 4.7HZ), 7.25 (q, 2H) , 7.09 (dd, 1H, J=5.04, 5.2Hz), 5.21-5.15 (m, 3H) IR (CH2C12) : cm"1
3630 (O-H) , 1690 (OO) Mass spectrum, m/e (relative intensity)
306 (M+, 100), 277 (22), 249 (29), 216 (21), 171 (13), 127 (13), 108 (10)
Preparation of 3-formyl-2-hvdroxymethyl-5- iodothiophene
To a solution of 3-dimethoxymethyl-2-formylthiophene (8.8 g) in methanol was added excess amount of sodium borohydride and stirred at room temperature for 2 hours. Methanol was removed and residue was dissolved in ethyl acetate. The solution was washed with water, dried over anhydrous magnesium sulfate and concentrated. The crude intermediate was then dissolved in methanol (40 ml) . Iodine (4.5 g) was added and then iodic acid (2.2 g) in water (10 ml)was added dropwisely. The solution mixture was stirred at room temperature for 4 hours. Methanol was removed and sodium thiosulfate (10%) was added to quench the unreacted iodine. Extracted with ethyl acetate, washed with brine, dried over anhydrous magnesium sulfate, concentrated and separated by silica gel chromatography to give yellowish oily product (10.4 g, 70%). Spectral Data: 1H NMR (CDC13) , δ value
9.87 (s, 1H) , 7.61 (s, 1H) , 4.98 (s, 2H) , 3.49 (s, 1H)
Preparation of 3-dimethoxγmethyl-2-formylthiophene
To a solution of 3-dimethoxymethylthiophene (14 g) in tetrahydrofuran (80 ml) was slowly added n-butyllithium (1.6 M in n-hexane, 47.8 ml) at -10°C with stirring. The reaction mixture was further stirred at same temperature for 1 hour. W,W-Dimethyl-formamide (11.9 g) in tetrahydrofuran (40 ml) was then added. The reaction mixture was warmed to room temperature and stirred for overnight. Ice water was added and extracted with ethyl acetate. The extract was dried over anhydrous magnesium sulfate and concentrated to give brownish oily product (13
g, 80%) .
Spectral Data: λE NMR (CDC13) ' δ value
10.25 (d, 1H, J=1.16Hz), 7.65 (dd, 1H, J=1.05, 4.03Hz), 7.24 (d, 1H, J=5.12Hz), 5.82 (s, 1H) , 3.38 (s, 6H)
Example 42
Synthesis of 4.5-dihydroxymethyl-2.2' :5' , 2"-terthiophene (NSC code # 663561) To a solution of 4-formyl-5-hydroxymethyl-2 , 2 ' : 5' , 2"- terthiophene (0.1 g) in methanol (10 ml) was added excess amount of sodium borohydride. The reaction mixture was stirred at room temperature for 40 minutes. Methanol was removed and water was added. The solution was extracted with ethyl acetate, washed with brine, dried over anhydrous magnesium sulfate and concentrated to give brownish solid product (0.1 g) , melting point 99-101°C. Spectral Data: λE NMR (CDCI3), δ value 7.42 (dd, 1H, J=6.29Hz), 7.28 (dd, 1H, J=1.13, 3.61Hz), 7.20-7.13 (m, 3H) ,
7.07 (dd, 1H, J=4.92, 5.29Hz), 4.77 (d, 2H, J=5.64Hz), 4.57 (d, 2H, J=5.70Hz) 4.28 (t, OH) , 3.68 (t, OH) IR (CHCI3) : cm"1 3630 (O-H) Mass spectrum, m/e (relative intensity)
308 (M+, 100), 291 (34), 262 (24), 261 (23), 217 (18), 216 (12), 171 (10), 127 (11)
Example 43
Synthesis of 5-formyl-4"-hydroxymethyl- 2.2 ' : 5 ' .2 "-terthiophene (NSC code # 658879) In a two-necked round bottomed flask was added
5-dimethoxymethyl-5 ' -tributyl-stannyl-2 , 2 ' -bithiophene (2.12 g, 4.0 mmole), bis (triphenylphosphine) -palladium (II) chloride (140 mg, 0.2 mmole), 2-iodo-4- hydroxymethylthiophene (0.96 g, 4.0 mmole) [prepared from sodium borohydride reduction of 2-iodo-4-formyl-thiophene (R. Guilard, P. Fournari, and M. Person, Bulletin De La Societe Chimique De France , 11, 4121, 1967) in tetrahydrofuran, 95% yield] and tetrahydrofuran (25 ml) . The reaction mixture was refluxed for 16 hours. To the reaction mixture was then added hydrochloric acid (I N, 3 ml) and was further refluxed for 3 hours. Saturated sodium bicarbonate aqueous solution was added to neutralize the solution and extracted with ethyl acetate. The extract was washed with brine, dried over anhydrous magnesium sulfate and concentrated. The residue was separated by silica gel chromatography, eluted with n-hexane/ethyl acetate (2:1) to give yellowish solid product (420 mg, 34%) , melting point 133-135°C. Spectral Data: ^-H NMR (CDC13) , δ value
9.86 (s, 1H) , 7.67 (d, 1H, J=8Hz) , 7.26-7.22 (m, 3H) , 7.16-7.11 (m, 2H) , 4.68 (s, 2H) IR (CH2C12) : cm"1 3620 (O-H), 1680 (C=0)
Mass spectrum, m/e (relative intensity)
306 (M+, 100), 233 (9), 69 (8), 28 (15)
Example 44
Synthesis of 5.4"-dihydroxymethyl-2 , 2' :5' .2"-terthiophene (NSC code # 658878) To a solution of 5-formyl-4"-hydroxymethyl-2 , 2 ' : 5' , 2"- terthiophene (140 mg) in methanol (10 ml) was added sodium borohydride (0.1 g) . The reaction mixture was stirred at room temperature for 40 minutes. Methanol was removed and water was added. The solution was extracted with ethyl acetate, washed with brine, dried over anhydrous magnesium sulfate and concentrated to give light yellowish solid product (140 mg) , melting point 111-113°C. Spectral Data: 1H NMR (CDC13) , δ value
7.18-7.02 (m, 5H) , 6.96-6.89 (m, 1H) , 5.30 (s, 1H) , 4.81 (brs, 2H) , 4.67 (s, 3H) IR (CHCI3) : cm"1
3650 (O-H) Mass spectrum, m/e (relative intensity)
308 (M+, 100), 292 (14), 291 (60), 275 (10)
Example 45 Synthesis of 5-formγl-3"-hydroxymethyl-2.2 ' : 5' .2"- terthiophene (NSC code # 658876) In a two-necked round bottomed flask was added
5-dimethoxymethyl-5 ' -tributyl-stannyl-2 , 2 ' -bithiophene (0.77 g) , bis (triphenylphosphine) palladium (II) chloride (0.06 g) , 3-hydroxymethyl-2-iodothiophene (0.38 g) and tetrahydrofuran (20 ml) . The reaction mixture was refluxed for 16 hours. To the reaction mixture was then added hydrochloric acid (I N, 10 ml) and was further refluxed for 3 hours. Saturated sodium bicarbonate aqueous solution was added to neutrality and extracted with ethyl acetate. The extract was washed with brine, dried over anhydrous magnesium sulfate and concentrated. The residue was
separated by silica gel chromatography, eluted with n-hexane/ethyl acetate (9:1 → 1:1 gradient) to give brownish solid product (0.24 g, 50%), melting point 85-86°C. Spectral Data: E NMR (CDC13) , δ value
9.86 (s, 1H) , 7.68 (dd, 1H, J=1.46, 3.96Hz), 7.32-7.24 (m, 3H),*
7.18-7.16 (m, 2H) , 4.80 (s, 2H) , 1.64 (bs, OH) IR (CH2C12) : cm"1
3630 (O-H) , 1680 (C=0) Mass spectrum, m/e (relative intensity)
306 (M+, 100), 289 (23), 273 (13), 227 (11), 203 (11) , 171 (18) , 121 (15)
Preparation of 3-hydroxymethyl-2-iodothiophene 3-Hydroxymethylthiophene (2.3 g, 20 mmole) (Aldrich Chem. Co., Milwaukee, WI) and iodine (2.39 g, 9.4 mmole) were dissolved in ethanol (15 ml). Iodic acid (1.09 g, 6.2 mmole) in water (2 ml) was added dropwisely at 0°C and was further stirred for 1 hour at the same temperature. The reaction was monitored with thin layer chromatography until the reaction was completed. Sodium thiosulfate aqueous solution was added and extracted with dichloromethane. T he extract was washed with brine, dried over anhydrous magnesium sulfate, concentrated and separated by silica gel chromatography, eluted with n-hexane/ethyl acetate (3:1) to give light yellowish oily product (3.9 g, 81%). Spectral Data: E NMR (CDCI3) , δ value
7.43 (d, 1H, J=5.2HZ), 6.96 (d, 1H, J=5.2Hz), 4.54 (s, 2H)
Example 46 Synthesis of 5.3"-dihvdroxγmethyl-2.2 ' : 5' .2"-terthiophene
(NSC code # 658875)
To a solution of 5-formyl-3"-hydroxymethyl-2,2' : 5' ,2"- terthiophene (60 mg) in tetrahydrofuran (5 ml) was added sodium borohydride (15 mg) . The reaction mixture was stirred at room temperature for 40 minutes.
Tetrahydrofuran was removed and water was added. The solution was extracted with ethyl acetate, washed with brine, dried over anhydrous magnesium sulfate and concentrated to give yellowish solid product (60 mg) , melting point 93-95°C. Spectral Data: E NMR (CDC13) , δ value
7.38 (d, 1H, J=5.3Hz), 7.21-7.13 (m, 3H) , 6.92 (d, 1H, J=2.65Hz) , 4.76 (d, 2H, J=6.0Hz), 4.71 (d, 2H, J=5.53Hz), 4.59 (t, 1H, J=5.5HZ, OH) , 4.35 (t, 1H, J=5.43Hz, OH) IR (CHCI3) : cm"1 3640 (O-H) Mass spectrum, m/e (relative intensity)
308 (M+, 100), 291 (44), 277 (13), 227 (11), 171 (13), 121 (13)
Example 47 The Preparation of Tartaric Acid Salt of Aminomethylterthiophene:
To an ethanolic solution (20 L) containing aminomethylterthiophene (300 mg, 1.08 mmol) was dropwisely added, with stirring, aqueous L-tartaric acid (2.160 mL, 05 M solution prepared from L-tartaric acid (600 mg, 4.0 mmol) in 8 mL of H20) . Ethanol was removed under vacuum and the residue was freeze-dried to give the salt (460 mg) .
The Preparation of (2:1) Hydroxypropyl-ø-cyclodextrin Complex of the Tartaric Acid Salt of
Aminomethylterthiophene:
To a solution containing hydroxypropyl-/3-cyclodextrin (3.60 g) in H20 (50 L) was added tartaric acid salt of aminomethylterthiophene (460 mg, 1.08 mmol) in one portion and sonicated for 10 minutes. The heterogeneous mixture was heated to near boiling with stirring until a clear solution was resulted. The solution was cooled to room temperature, gravity filtered, and freeze-dried to give (2:1) hydroxypropyl-3-cyclodextrin complex of the tartaric acid salt of aminomethylterthiophene.
The Quantitative Calculation of the Amount of
Aminomethylterthiophene in (2:1) Hydroxypropyl-3- cyclodextrin Complex of the Tartaric Acid Salt of Aminomethylterthiophene:
To 25.21 mg of the (2:1) cyclodextrin complex was added
1.10 mg (0.0079 mmol) of nitrophenol and was dissolved in
D20 (1 mL) for λE NMR. The ration of aminomethylterthiophene to nitrophenol calculated from the 1H NMR integration was 89%.
0.0079 mmol (nitrophenol) x 0.89 = 0.00704 mmol
(aminomethylterthiophene)
0.00704 mmol x 277g/mol (m.wt. of aminomethylterthiophene)
= 1.95 mg Since 1.95 mg of aminomethylterthiophene is in 25.21 mg of the cyclodextrin complex, 1.0 mg of aminomethylterthiophene is in 12.93 mg of the cyclodextrin complex.
The solubility of cyclodextrin complex in H20 was tested by dropwisely adding H20 to 30 mg of the cyclodextrin complex, with stirring. The result showed that the 30 mg of the cyclodextrin complex, containing 2.32 mg of aminomethylterthiophene, can be dissolved in 30 μL of H20 to give clear syrup. The result suggests that 1 mL of H20 can dissolve up to 77 mg of aminomethylterthiophene (1000
mg of the cyclodextrin complex) to give clear syrup.
Example 48
Other polythiophene compounds prepared in accordance with this invention are those represented by the following structural formulas.
^« .^J— CH2OCOCH3
20
CH3OC- -COCH,
II — IL -CH=CBr2
-C≤C— CH— CHjOH I OAc
-CsC— CHCHjOH OCOC17H33
-C«C— C02E:
-CH-NOH
*s-
H,C- -CHO
HOH2C- -CHO
CH3(CH2) -CH2OH
OHC- CH2OCOCH3
HOH-C- -CHO
_^ ^S'
-CsC— CH2OAc
Example 49
Additional National Cancer Institute data demonstrating polythiophene growth inhibition of human cancer cell lines is represented in the following tables. The compound must exhibit a Log10 GI50 value of <-4.00 to be considered active against the tested cell line.
NSC: 659567-P/0-1/34
NSC: 660642-W/0-1/11
NSC: 647452-L/l
NSC: 660644-Y/0-2/12
NSC: 663562-V/O-1/18
NSC: 666165-Z/0-1/30
NSC: 658878-G/0-1/16
NSC: 652866-U/l
NSC: 647455-O/1
HOHiC- ^V -CHO
NSC: 637388-V/l
NSC: 637393-A/l
NSC: 647455-O/1
HOHzC- CHO
S"
NSC: 646270-Z/l
NSC: 666710-S/0-1/9
NSC: 665150-W/0-1/15
In Vivo Antitumor Activity
The following experiments were carried out at Purdue University athymic mouse laboratory. Athymiσ mice were purchased from and maintained at the athymic mouse laboratory under pathogenic conditions. Tumor cells (TBE) were obtained from normal human bronchial epithelial cells transfected'with plasmic HI carrying v-Harvey-ras (H-ras) oncogene via protoplast fusion (G.H. Yoakum, J.F. Lechner, E.W. Gabrielson, B.E. Korba, L. Malan-Shibley, J.C. Willey, M.G. Valerio, A.M. Shamsuddin, B.F. Trump and C.C. Harris, Science 227, 1174, 1985. T.C.K. Chan, C.-j. Chang, N.M. Koonchanok and R.L. Geahlen, Biochem . Biophys . Res . Commun . , 193, 1152, 1993. The TBE cells were implanted subcutaneously on day 0 of the experiment. Each test group consists of five mice. The compounds tested were dissolved in a saline solution or a saline solution containing 5% of dimethylsulfoxide and 10% cremphor EL (Sigma Chemical Company, St. Louis, MO) , and were administered intraperitoneously starting on day 2. The solution was administered every four days for a total of four treatments. Tumor volumes were measured every week. The antitumor activity was measured as % of growth inhibition, which is defined by the percentage of the median tumor volume reduction per week of the treated mice divided by the median tumor volume per week of the controlled mice (Tables 9 and 10) .
Table 9. Antitumor Efficacy of 5-Aminomethyl-α- terthiophene Tartarate-Hydroxypropyl-ø-cyclodextrin Complex (NSC Code #660641)
Tumor cells: ras-transformed human bronchial epithelial cells (2.5 x 106 cells/mouse)
Formulation: saline solution
1. Control
Number of Tumor Volume Slope Tumor Growth Week Animals with (mm3) (mm3/week) Inhibition Tumor (%)
1 1 1.3 2 1 1.3 3 3 14.7 4.41 4 3 16.0 4.54 5 3 19.3 4.40 6 3 24.3 4.41 7 3 34.7 4.92 8 3 34.3 4.80
2. 12 mg/kg
Number of Tumor Volume Slope Tumor Growth Week Animals with (mm3) (mm3 /week) Inhibition Tumor ( % )
1 0 0.0 2 0 0.0 3 1 1.2 0.36 92 4 2 4.8 1.08 76 5 2 4.8 1.13 74 6 2 4.8 1.03 77 7 4 8.2 1.18 76 8 5 24.0 2.34 51
* Tumor Growth Inhibition (%) = Slope (control) - Slope (treated) x 100
Slope (control)
Table 10. Antitumor Efficacy of 5-Hydroxγmethyl-5"- formyl-α-terthiophene (NSC Code #647455)
Tumor cells: ras-transformed human bronchial epithelial cells (4.0 x 106 cells/mouse)
Formulation: 5% DMSO and 10% cremphor in saline solution l. control
Number of Tumor Volume Slope Tumor Growth Week Animals with (mm3) (mma33//wweeeekk)) Inhibition Tumor (%)
1 2 2.4
1.5 3 6.2
2 4 10.8
3 4 14.6 4.97
4 4 15.8 4.37
5 4 15.0 3.45
6 4 16.6 2.91
8.6 5 23.6 2.63
2. 25 mg/kg
Number • Of Tumor Volume Slope Tumor Growth
Week Animals with (mm3) (mm3 /week) Inhibition Tumor ( % )
1 0 0.0
1.5 1 1.4
2 3 5.2
3 4 5.8 2.16 57
4 4 5.6 1.75 60
5 4 5.4 1.34 61
6 5 10.6 1.60 45
8.6 5 18.8 2.07 21
* Tumor Growth Inhibit: Lon (%) = Slope (control) - Slope (treated) x 100
Slope (control)
Example 51
Human tumor cells of various origins (kidney, skin, ovary and lung cell lines) were implanted into athymic mice and injected intraperitoneally with polythiophene compounds of the present claims. The tumor cells were implanted at various sites: subcutaneous, intraperitoneal and subrenal. At predetermined times after tumor implantation, polythiophene compositions were administered intraperitoneally to the test group mice according to the drug schedule indicated by code in table 11. The first number of the code indicates the interval between treatments, the second number indicates the total number of times the drug was administered and the superscript letter indicates the first day of treatment. Thus the designation Q4d x 3d indicates the treatments were initiated 15 days after implantation and a total of three treatments were administered at intervals of four days. Tumor growth inhibition was determined by comparing the volume/weight of the tumors of the treated mice in the test group with that of the tumors in the control group mice. The data are presented as the percent of treated tumor volume/weight to control tumor volume/weight (T/C %) with the day the measurement was taken indicated in parenthesis.
Table 11. Evaluation of In Vivo Antitumor Efficacy of Polythiophenes
Compound* Implant* Drug* Drug T/C %k
NSC# Tumor (Origin) Site Dosage(mg/kg) Schedule (Day)
660641 A-498(kidney) SC 175 Q4D 3' 46(29)
CAKI-l(kidney) SC 157 QD x5* 44(36)
UACC-257(s in) SC 175 Q7D x3# 53(33)
TBE(lung) SC 155 Q4D x4' 24(49)
P-388(lymphocyte) IP 225 QDx5« Inactive
647455 TBE (lung) SC 25 Q4Dx 4f 39(35)
637388 CAH-1 (kidney) SR 50 Q4Dx3k 16(13)
658878 TBE (lung) SC 40 Q4D x4' 5(70)
666710 A-498(kidney) SC 60 Q4DX45 45(38)
a. 660641: hydroxypropyl-B-cyclodextrin inclusion complex of 2-aminohydroxy-α- terthiophene tartarated (2:1 molar ratio; FW:3428) (Estimated 50% lethal dosage: 1550 mg/kg.) 647455: 2-formyl-5"-hydroxymethyl-α-terthiophene 637388: 2-hydroxymethyl -α-terthiophene 658878: 2,4"-<lihydroxymethyl-α-terthiophene
666710: 2-hydroxymethyl-α-terthiophene /S-D-glucoside b. SC: subcutaneous; IP: intraperitoneal; SR: subrenal c. Drug was administered intraperitoneally. d-j. First day of drug treatment, d: Day 15; e: Day 12; f:Day 3; g: Day 1; h: Day 2; i: Day 14; j: Day 10. k. T/C: tumor volume or weight of treated mice/tumor volume or weight of control (untreated) mice. The number shown in the parenthesis is the day when the tumor volume or weight is measured.
Claims
1 . A compound of the formula :
wherein n is 0 , 1 or 2 ,
R-L is H , CH2OH , CHO , CH2NH2 ,
R2 and R 3 are independently selected from the group consisting of 2-thienyl, 3-thienyl, mono- or di- substituted 2-thienyl, or mono- or di- substituted 3-thienyl, wherein the thienyl substituents are selected from the group consisting of cyano, chloro, bromo, iodo, C- -C-η alkyl or haloalkyl, C- -Cη alkenyl or haloalkenyl, cι~c 4 alkanoyloxy methyl, CH2OR4, COR5, CH2NR6R7, CH(OR4)R8, CH=CR9R10, CH=NR11, CH2SC(NH)NH2 and C≡CR12 wherein
R4 is H, CO(CH2)2C02H, (CH2)2OCH3, C±-C4 alkyl, COC1-C17 alkyl, or tetrahydropyranyl;
R5 is H or C -Cη alkyl;
R6 and R7 are independently H, mono- or di- hydroxyC2-C4 alkyl ;
R8 is C_-Cη alkyl, or C_- η alkenyl;
R9 and R10 are independently H, _-Cη alkyl, COOR 5' CN, CH(OR4)COOR5, Br, CO-thienyl, or COC6H4OH(p) ;
Rlχ is NHR4 or OR5;
R12 is COOR5, CH(OR4)CH2OR13 or CH (OCOC-L-^ alkyl) CH2OR5;
R13 is H, COCH2CH2COOH, or COC1-C17 alkyl; cyclodextrin complexes of such compound; and when R2 or R3 is thienyl substituted with CH2NR6R7, the pharmaceutically acceptable salt of the compound represented thereby; with the proviso, that when Rλ is H, R2 is selected from the group consisting of 3-thienyl, di- substituted 2-thienyl, hydroxymethyl- or aminomethyl- substituted 2-thienyl, 3-formy1-2-thienyl and mono- or di- substituted 3-thienyl, and R3 is selected from the group consisting of 3-thienyl, di- substituted 2-thienyl, hydroxymethyl- or aminomethyl- substituted 2-thienyl, mono- or di- substituted 3-thienyl and formy1 substituted 2-thienyl.
2. The compound of claim 1, wherein n = 1, R is H, R2 is 3-thienyl or substituted 3-thienyl and R3 is 2-thienyl or substituted 2-thienyl.
3. The compound of claim 2 wherein R2 is 3-thienyl and R3 is substituted 2-thienyl wherein the substituents are selected from the group consisting of CH2NH2 CH2OH or CHO.
4. The compound of claim 1, wherein n = 1, Rχ is hydrogen, and R2 is hydroxymethyl 2-thienyl and R3 is substituted 2-thienyl wherein the substituents are selected from the group consisting of CH2NH2, CH20H or CHO.
5. The compound of claim 1 wherein n = 2.
6. The compound of claim 1 wherein n = 0.
7. The compound of claim 1 wherein R2 is 2-thienyl or substituted 2-thienyl and R3 is 3- or 4-substituted-2-thienyl wherein the substituents are selected from the group consisting of CH2OH, CHO and CH2NH2.
8. A compound of the formula:
Rλ is H, CH2OH, CHO, CH2NH2 ,
R is selected from the group consisting of 2-thienyl, 3- thienyl, mono- or di- substituted 2-thienyl, and mono- or di- substituted 3-thienyl, and R3 is selected from the group consisting of 3-thienyl, mono- or di- substituted 3-thienyl, and di- substituted 2-thienyl, wherein the thienyl substituents are selected from the group consisting of cyano, chloro, bromo, iodo, C-^C-j alkyl or haloalkyl, C_-C7 alkenyl or haloalkenyl, ι~ 4 alkanoyloxy methyl, CH2OR4, COR5, CH2NR6R7, CH(OR4)R8, CH=CR9R10, CH=NR1;L, CH2SC(NH)NH2 and C≡CR12 wherein
R4 is H, CO(CH2)2C02H, (CH2)2OCH3, or 00^-0.^ alkyl;
R5 is H or C-L-CJ alkyl; R6 and R7 are independently H, C^^ alkyl, or mono- or di- hydroxyC2-C4 alkyl;
R8 is C1-C7 alkyl, or 0 -07 alkenyl;
R9 and R10 are independently H, ^\-Cη alkyl, C00R5, CN CH(OR4)COOR5, Br, CO-thienyl, or COC6H4OH(p) ; Rlλ is NHR4 or 0R5;
R12 is COOR5, CH(OR4)CH2OR13 or CH(OCOC1-C4 alkyl) CH2OR5;
R13 is H, COCH2CH2COOH, or COC^C-]^ alkyl; cyclodextrin complexes of such compound and when R2 or R3 is thienyl substituted with CH2NR6R7, the pharmaceutically acceptable salt of the compound represented thereby.
9. A composition comprising an anti-tumor effective amount of a compound of the formula:
R-L is H, CH2OH, CHO, CH2NH2 ,
R2 and R3 are independently selected from the group consisting of 2-thienyl, 3-thienyl, mono- or di- substituted 2-thienyl, or mono- or di- substituted 3-thienyl, wherein the thienyl substituents are selected from the group consisting of cyano, chloro, bromo, iodo, C- -Cη alkyl or haloalkyl, C -Cη alkenyl or haloalkenyl, cι~C4 alkanoyloxy methyl, CH2OR4, C0R5, CH2NR6R7, CH(0R4)R8, CH=CRgR10 , CH=NR1X, CH2SC(NH)NH2 and C≡CR12 wherein
R4 is H, CO(CH2)2C02H, (CH2)2OCH3, or COC^-C^ alkyl;
R5 is H or Cλ-Cη alkyl;
R6 and R7 are independently H, C -C^ alkyl, or mono- or di- hydroxyC2-C4 alkyl;
R8 is C-L-Cy alkyl, or C -C7 alkenyl;
R9 and R10 are independently H, C-^-C-j alkyl, COOR5, CN, CH(OR4)COOR5, Br, CO-thienyl, or COC6H4OH(p) ;
Rl is NHR4 or OR5; R12 is COOR5, CH(OR4)CH2OR13 or CH(OCOC1-C4 alkyl) CH2OR5;
R13 is H, COCH2CH2COOH, or COC^C-^ alkyl; cyclodextrin complexes of such compound and when R2 or R3 is thienyl substituted with CH2NR6R7, the pharmaceutically acceptable salt of the compound represented thereby; with the proviso, that when λ is H, R2 is selected from the group consisting of 2-thienyl, 3-thienyl, mono- or di- substituted 2-thienyl, or mono- or di- substituted 3-thienyl, and R3 is selected from the group consisting of 3-thienyl, mono- or di- substituted 2-thienyl, or mono- or di- substituted 3-thienyl and a pharmaceutically acceptable carrier.
10. The composition of claim 9 wherein n = 1, Rj is H, R2 is 3-thienyl or substituted 3-thienyl and R3 is 2-thienyl or substituted 2-thienyl.
11. The composition of claim 9 wherein R2 is 3-thienyl and R3 is substituted 2-thienyl wherein the substituents are selected from the group consisting of CH2NH2 CH2OH or CHO.
12. The composition of claim 9 wherein n = 1, Rx is hydrogen, and R2 is hydroxymethyl 2-thienyl and R3 is substituted 2-thienyl wherein the substituents are selected from the group consisting of CH2NH2, CH20H or CHO.
13. The composition of claim 9 wherein n = 2.
14. The composition of claim 9 wherein n = 0.
15. The composition of claim 9 wherein R2 is 2-thienyl or substituted 2-thienyl and R3 is 3- or 4-substituted-2-thienyl wherein the substituents are selected from the group consisting of CH20H, CHO and CH2NH2.
16. A composition comprising an anti-tumor effective amount of a compound of the formula:
wherein n is 0, 1 or 2 ,
R is H, CH20H, CHO, CH2NH2 , R2 is selected from the group consisting of 2-thienyl, 3- thienyl, mono- or di- substituted 2-thienyl, or mono- or di- substituted 3-thienyl, and R3 is selected from the group consisting of 3-thienyl, mono- or di- substituted 3-thienyl, di- substituted 2-thienyl wherein the thienyl substituents are selected from the group consisting of cyano, chloro, bromo, iodo, C-L-C-7 alkyl or haloalkyl, C-L-C7 alkenyl or haloalkenyl, C^C^ alkanoyloxy methyl, CH2OR4, C0R5, CH2NR6R7, CH(OR4)R8, CH=CR9R10, CH=NR11, CH2SC(NH)NH2 and e≡CR12 wherein
R4 is H, CO(CH2)2C02H, (CH2)2OCH3, C^^ alkyl or COC^C-^ alkyl;
R5 is H or C -C7 alkyl;
R6 and R7 are independently H, C- -C4 alkyl, or mono- or di- hydroxyC2-C4.alkyl;
R8 is ^-07 alkyl, or C -Cη alkenyl; Rg and R10 are independently H, C-^-Cη alkyl, COOR5, CN, CH(OR4)COOR5, Br, CO-thienyl, or COC6H4OH(p);
Rλl is NHR4 or 0R5;
R12 is C00R5, CH(0R4)CH20R13 or CH(OCOC1-C4 alkyl) CH2OR5;
R13 is H, COCH2CH2COOH, or COC^C-^ alkyl; cyclodextrin complexes of such compound and when R2 or R3 is thienyl substituted with CH2NR6R7, the pharmaceutically acceptable salt of the compound represented thereby, and a pharmaceutically acceptable carrier.
17. A method of treating a patient having a tumor, said method comprising the step of administering to the patient an effective amount of a compound of the formula:
wherein n is 0, l or 2,
Rλ is H, CH2OH, CHO, CH2NH2 ,
R2 and R3 are independently selected from the group consisting of 2-thienyl, 3-thienyl, mono- or di- substituted 2-thienyl, or mono- or di- substituted 3-thienyl, wherein the thienyl substituents are selected from the group consisting of cyano, chloro, bromo, iodo, ^-07 alkyl or haloalkyl, ^-07 alkenyl or haloalkenyl, C1-C4 alkanoyloxy methyl, CH2OR4, COR5, CH2NR6R7, CH(OR4)R8, CH=CRgR10, CH=NRlχ, CH2SC(NH)NH2 and C≡CR12 wherein
R4 is H, CO(CH2)2C02H, (CH2)2OCH3, 0^4 alkyl or ακ^-C-,^ alkyl;
R5 is H or C-L-C7 alkyl;
R5 and R7 are independently H, C^ -C^ alkyl, or mono- or di- hydroxyC2-C4 alkyl;
R8 is Cλ-C7 alkyl, or C^ η alkenyl;
R9 and R10 are independently H, C-^-C^ alkyl, COOR5, CN CH(OR4)COOR5, Br, CO-thienyl, or COC6H4OH(p) ; Rl is NHR4 or OR5; R12 is COOR5, CH(OR4)CH2OR13 or CH(OCOC1-C4 alkyl) CH2OR5 ; R13 is H, COCH2CH2COOH, or COC-^-C^ alkyl; cyclodextrin complexes of such compound and when R2 or R3 is thienyl substituted with CH2NR6R7, the pharmaceutically acceptable salt of the compound represented thereby; with the proviso, that when R± is H, R2 is selected from the group consisting of
2-thienyl, 3-thienyl, mono- or di- substituted 2-thienyl, or mono- or di- substituted 3-thienyl, and R3 is selected from the group consisting of 3-thienyl, mono- or di- substituted 2-thienyl, or mono- or di- substituted 3-thienyl.
18. The method of claim 17 wherein n = 1, Rλ is H, R2 is 3-thienyl or substituted 3-thienyl and R3 is 2-thienyl or substituted 2-thienyl.
19. The method of claim 17 wherein R2 is 3-thienyl and R3 is substituted 2-thienyl wherein the substituents are selected from the group consisting of CH2NH2 CH2OH or CHO.
20. The method of claim 17 wherein n = 1, R is hydrogen, and R2 is hydroxymethyl 2-thienyl and R3 is substituted 2- thienyl wherein the substituents are selected from the group consisting of CH2NH2, CH2OH or CHO.
21. The method of claim 17 wherein n = 2.
22. The method of claim 17 wherein n = 0.
23. The method of claim 17 wherein R2 is 2-thienyl or substituted 2-thienyl and R3 is 3- or 4-substituted-2-thienyl wherein the substituents are selected from the group consisting of CH20H, CHO and CH2NH2.
24. A method for treating a patient having a tumor, said method comprising the step of administering to the patient an effective amount of a compound of the formula:
wherein n is 0, 1 or 2 ,
R-L is H, CH20H, CHO, CH2NH2 ,
R2 is selected from the group consisting of 2-thienyl, 3- thienyl, mono- or di- substituted 2-thienyl, or mono- or di- substituted 3-thienyl, and R3 is selected from the group consisting of 3-thienyl, mono- or di- substituted 3-thienyl, and di- substituted 2-thienyl, wherein the thienyl substituents are selected from the group consisting of cyano, chloro, bromo, iodo, ^-07 alkyl or haloalkyl, C^C; alkenyl or haloalkenyl, ι~ 4 alkanoyloxy methyl, CH2OR4, COR5, CH2NR6R7, CH(OR4)R8, CH=CRgR10, CH=NR11, CH2SC(NH)NH2 and C≡CR12 wherein
R4 is H, CO(CH2)2C02H, (CH2)2OCH3, ^-04 alkyl or COC^C-^ alkyl; R5 is H or ^-07 alkyl; R6 and R7 are independently H, ^-04 alkyl, or mono- or di- hydroxyC2-C4 alkyl;
R8 is C2.-C7 alkyl, or ^-07 alkenyl;
R9 and R10 are independently H, C-^-Cη alkyl, COOR5, CN, CH(OR4)COOR5, Br, CO-thienyl, or COC6H4OH(p);
Rλl is NHR4 or OR5;
R12 is COOR5, CH(OR4)CH2OR13 or CH(OCOC1-C4 alkyl) CH2OR5 ;
R13 is H, COCH2CH2COOH, or COC^C-^ alkyl; cyclodextrin complexes of such compound and when R2 or R3 is thienyl substituted with CH2NR6R7, the pharmaceutically acceptable salt of the compound represented thereby.
Priority Applications (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US1996/019118 WO1998023269A1 (en) | 1996-11-26 | 1996-11-26 | Polythiophene anti-tumor agents |
| AU15647/97A AU1564797A (en) | 1996-11-26 | 1996-11-26 | Polythiophene anti-tumor agents |
| EP96945379A EP1007035A4 (en) | 1996-11-26 | 1996-11-26 | Polythiophene anti-tumor agents |
| JP52659098A JP2001506624A (en) | 1996-11-26 | 1996-11-26 | Polythiophene antitumor agent |
| CA002272275A CA2272275A1 (en) | 1996-11-26 | 1996-11-26 | Polythiophene anti-tumor agents |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US1996/019118 WO1998023269A1 (en) | 1996-11-26 | 1996-11-26 | Polythiophene anti-tumor agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1998023269A1 true WO1998023269A1 (en) | 1998-06-04 |
Family
ID=22256220
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US1996/019118 WO1998023269A1 (en) | 1996-11-26 | 1996-11-26 | Polythiophene anti-tumor agents |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1007035A4 (en) |
| JP (1) | JP2001506624A (en) |
| AU (1) | AU1564797A (en) |
| CA (1) | CA2272275A1 (en) |
| WO (1) | WO1998023269A1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010044743A1 (en) * | 2008-10-17 | 2010-04-22 | Biochromix Pharma Ab | Novel thiophene compounds for use in theraphy |
| CN113603674A (en) * | 2021-07-23 | 2021-11-05 | 上海应用技术大学 | 5,5 '-substituted 3, 3' -bithiophene derivative, and synthesis method and application thereof |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1831205A4 (en) * | 2004-09-14 | 2010-12-01 | Univ Northwestern | Carbonyl-functionalized thiophene compounds and related device structures |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3050442A (en) * | 1957-05-31 | 1962-08-21 | Philips Corp | Method of destroying nematodes with polythienyl compounds |
| US4861692A (en) * | 1986-12-22 | 1989-08-29 | Fuji Electric Company, Ltd. | Electrophotographic photosensitive material containing thiophene compound |
| US5045563A (en) * | 1986-08-26 | 1991-09-03 | Her Majesty The Queen In Right Of Canada, As Represented By Minister Of National Defence Of Her Majesty's Canadian Government | Phototoxic compounds for use as insect control agents |
| US5252191A (en) * | 1990-04-27 | 1993-10-12 | Duphar International Research B.V. | Method for the photochemical isomerization of organic compounds under the influence of a photosensitizer |
| US5578636A (en) * | 1994-04-08 | 1996-11-26 | Purdue Research Foundation | Polythiophene anti-tumor agents |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3818670A1 (en) * | 1988-06-01 | 1989-12-14 | Basf Ag | polythiophene compounds |
| US5508440A (en) * | 1993-06-04 | 1996-04-16 | Industrial Technology Research Institute | Hydroxymethylpolythiophene derivatives |
-
1996
- 1996-11-26 EP EP96945379A patent/EP1007035A4/en not_active Withdrawn
- 1996-11-26 CA CA002272275A patent/CA2272275A1/en not_active Abandoned
- 1996-11-26 WO PCT/US1996/019118 patent/WO1998023269A1/en not_active Application Discontinuation
- 1996-11-26 JP JP52659098A patent/JP2001506624A/en active Pending
- 1996-11-26 AU AU15647/97A patent/AU1564797A/en not_active Abandoned
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3050442A (en) * | 1957-05-31 | 1962-08-21 | Philips Corp | Method of destroying nematodes with polythienyl compounds |
| US5045563A (en) * | 1986-08-26 | 1991-09-03 | Her Majesty The Queen In Right Of Canada, As Represented By Minister Of National Defence Of Her Majesty's Canadian Government | Phototoxic compounds for use as insect control agents |
| US4861692A (en) * | 1986-12-22 | 1989-08-29 | Fuji Electric Company, Ltd. | Electrophotographic photosensitive material containing thiophene compound |
| US5252191A (en) * | 1990-04-27 | 1993-10-12 | Duphar International Research B.V. | Method for the photochemical isomerization of organic compounds under the influence of a photosensitizer |
| US5578636A (en) * | 1994-04-08 | 1996-11-26 | Purdue Research Foundation | Polythiophene anti-tumor agents |
Non-Patent Citations (1)
| Title |
|---|
| See also references of EP1007035A4 * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010044743A1 (en) * | 2008-10-17 | 2010-04-22 | Biochromix Pharma Ab | Novel thiophene compounds for use in theraphy |
| CN102256959A (en) * | 2008-10-17 | 2011-11-23 | 比奥克罗密克斯药业有限公司 | Novel thiophene compounds for use in theraphy |
| CN102256959B (en) * | 2008-10-17 | 2014-01-08 | 比奥克罗密克斯药业有限公司 | Novel thiophene compounds for use in theraphy |
| US8710246B2 (en) | 2008-10-17 | 2014-04-29 | Biochromix Newco Ab | Substituted thiophene pentamers |
| KR101743049B1 (en) | 2008-10-17 | 2017-06-02 | 바이오크로믹스 파마 에이비 | Novel thiophene compounds for use in theraphy |
| CN113603674A (en) * | 2021-07-23 | 2021-11-05 | 上海应用技术大学 | 5,5 '-substituted 3, 3' -bithiophene derivative, and synthesis method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1007035A4 (en) | 2000-11-22 |
| JP2001506624A (en) | 2001-05-22 |
| CA2272275A1 (en) | 1998-06-04 |
| AU1564797A (en) | 1998-06-22 |
| EP1007035A1 (en) | 2000-06-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2013265119B2 (en) | Catechol O-methyltransferase activity inhibiting compounds | |
| JPH01211576A (en) | Novel 2, 5-diaryltetrahydrofran and its analogue as paf antagonist | |
| US20040063662A1 (en) | Selenophene anti-tumor agents | |
| US5578636A (en) | Polythiophene anti-tumor agents | |
| WO2005007635A2 (en) | Combretastatin derivatives with cytotoxic action | |
| WO1998023269A1 (en) | Polythiophene anti-tumor agents | |
| CN113620969B (en) | Cyclohexane dicarboxylic acid derivative with bridged ring, and pharmaceutical composition and application thereof | |
| AU2007249952B2 (en) | Modified chalcone compounds as antimitotic agents | |
| CN104650109B (en) | Bearing taxanes | |
| AU727123B2 (en) | Selenophene anti-tumor agents | |
| JP2000511897A (en) | Novel water-soluble analog of 20 (S) camptothecin | |
| US5994394A (en) | Polyheterocyclic compounds | |
| CN114230466A (en) | Dichloroacetic acid coupled diphenylethane compound, preparation method and application thereof | |
| US4520028A (en) | α-Aminobutyric acid transaminase inhibitors | |
| TW304951B (en) | Polythiophene anti-tumor compound and pharmaceutical composition | |
| US4524076A (en) | Novel γ-aminobutyric acid transaminase inhibitors | |
| AU2002238760B2 (en) | Antiproliferative agents | |
| NL8501776A (en) | PRECURSORS FOR MEDICINAL PRODUCTS, PROCESS FOR PREPARING THEREOF, AND PHARMACEUTICAL PREPARATIONS BASED THEREOF. | |
| Schachtner et al. | Synthesis and anticonvulsive activity of thiolosigamone | |
| KR100501843B1 (en) | New Anti-carcinogenic Vitamin D3 Analogs | |
| KR100248329B1 (en) | Novel genipin derivative and therapeutic composition for liver disease comprising the same as an active ingredient | |
| JPH1180152A (en) | Polyheterocyclic compound | |
| Stecoza et al. | SYNTHESIS AND STRUCTURE ELUCIDATION OF SOME NEW O-ACYL-OXIMINO-DIBENZO [b, e] THIEPINES AND O-ACYL-OXIMINO-DIBENZO [b, e] THIEPINE-5, 5-DIOXIDES | |
| AU2002238760A1 (en) | Antiproliferative agents | |
| NO175099B (en) | Analogous Process for Preparation of Therapeutically Active 1,3,5-Tritian Derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WWE | Wipo information: entry into national phase |
Ref document number: 96180518.8 Country of ref document: CN |
|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| ENP | Entry into the national phase |
Ref document number: 2272275 Country of ref document: CA |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 1996945379 Country of ref document: EP |
|
| ENP | Entry into the national phase |
Ref document number: 1998 526590 Country of ref document: JP Kind code of ref document: A |
|
| REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
| WWP | Wipo information: published in national office |
Ref document number: 1996945379 Country of ref document: EP |
|
| WWW | Wipo information: withdrawn in national office |
Ref document number: 1996945379 Country of ref document: EP |